



 **MEDIFAST**® | **Trilivy**™

Clinical Studies Overview

Table of Contents

Our Scientific Heritage & Distinguished Scientific Advisory Board.....	4
Medifast® Clinical Research Studies	
The 5 & 1 Plan®	
Arterburn (2019)	7
Shikany (2013)	8
Coleman (2012).....	9
Davis (2010).....	10
The 4 & 2 & 1 Plan®	
Coleman (2015).....	12
Beavers (2018).....	13
Normandin (2018).....	14
Dearborn (2023).....	15
Justice (2024).....	16
The 5 & 2 & 2 Plan®	
Kiel (2015)	18
Hamilton-Reeves (2020).....	19
Dimachkie (2021)	20
Betchel (2024).....	21
Diabetes	
Coleman (2017).....	23
Cheskin (2008).....	24
Healthy Habits and Early Indicators of Success	
Coleman (2022).....	26
Coleman (2023).....	27
Vernarelli (2024).....	28
Medifast® Products and Recipes	
Miller (2021)	30
Davis (2008)	31



**Obesity Pharmacotherapy &
Non-Pharmaceutical Appetite Suppressants**

Grosicki (2025).....	33
Grosicki (2024).....	34
Moldovan (2016).....	35
Haddock (2008).....	36
Matalon (2000).....	37

Polycystic Ovarian Syndrome (PCOS)

Yuh (2011).....	39
-----------------	----

Seniors

Miller (2021).....	41
Quillen (2020).....	42
Serra (2019).....	43
Weaver (2019).....	44
Beavers (2018).....	45
Shaver (2018).....	46
Normandin (2018).....	47
Kelleher (2017).....	48
Beavers (2015).....	49

Soy

Messina (2022).....	51
Messina (2022).....	52

Teenagers

Cheskin (2007).....	54
---------------------	----

Trp64Arg Gene Variant

Tchernof (2000).....	56
----------------------	----

Other – General Health and Nutrition Research

Lynch (2025).....	58
Beavers (2023).....	59
Mischra (2023).....	60

Our Scientific Heritage & Distinguished Scientific Advisory Board

The long-standing scientific heritage of Medifast[®], the company behind Trilivy[™], combined with the support of a Trilivy coach and like-minded Trilivy community, clinically proven programs, and scientifically designed products is what makes us a comprehensive approach to Lifelong Transformation through Metabolic Science and Human Connection. All of our programs feature a combination of Trilivy products, conventional food choices, easy-to-understand meal plans, and customizable levels of support for weight loss and weight maintenance—all backed by our team of registered dietitian nutritionists, behavioral experts, and food scientists.

The Medifast Scientific Advisory Board was first formed in 2008. It is comprised of internationally recognized experts, all of whom have made significant contributions in their respective field. The function of the Scientific Advisory Board is to provide objective insight and external expertise to help guide Medifast in making informed, evidence-based decisions on medical, nutritional, and scientific matters. The Scientific Advisory Board serves as a part of our foundation to create scientifically-valid, consumer-centric, high-quality innovations for lasting health.

This cross-disciplinary group consists of distinguished physicians, academic researchers, nutrition and health-related experts. The work of this prestigious board builds on Medifast's scientific and clinical heritage, which focuses on sound approaches to weight management while exploring forward-looking innovations, product and program offerings, and clinical research opportunities.

The clinical research cited throughout this overview refers to the foundational plans (such as the Optimal Weight 5 & 1 Plan[®]) originally studied by Medifast, Inc./OPTAVIA[®]. These plans have since been rebranded and are part of the Trilivy[™] comprehensive metabolic health system.



**For more information on
the current Scientific Advisory
Board Members, please visit:
[Medfastinc.com/About-Us](https://www.medfastinc.com/About-Us)**



The 5 & 1 Plan[®]

Arterburn (2019)

Randomized Controlled Trial Assessing Two Commercial Weight Loss Programs in Adults with Overweight or Obesity

LM Arterburn¹, CD Coleman¹, J Kiel¹, K Kelley², L Mantilla², N Frye¹, K Sanoshy², CM Cook²

¹Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland, USA; ²Biofortis, Mérieux NutriSciences, Addison, IL, USA.

PURPOSE/OBJECTIVE:

Lifestyle interventions remain the cornerstone for obesity treatment. Commercial programs offer one weight loss approach, yet the efficacy of few such programs have been rigorously investigated. The purpose of this study was to evaluate the efficacy of two commercial weight-loss programs, both utilizing pre-portioned meal replacements (MRs) and different levels of behavioral support, compared to a self-directed control diet in adults with overweight and obesity.

METHODS/DESIGN:

In this 16-week study, participants were randomized to the low-calorie OPTAVIA® 5 & 1 Plan® with telephone coaching (OPT), the reduced-calorie Medifast® 4 & 2 & 1 self-guided plan (MED), or a self-directed, reduced-calorie control diet. Differences in weight, body composition (DXA) and body circumferences, all measured monthly, were assessed by analysis of covariance with sex and baseline measures as covariates.

RESULTS:

Of 198 participants randomized (80.8% female, BMI 34.2 kg/m², 45.7 years), 92.3% completed the study.

The OPT and MED groups had significantly greater reductions in body weight (-5.7% and -5.0%, respectively, $p < 0.0001$), fat and abdominal fat mass ($p < 0.0001$) and waist and hip circumferences ($p \leq 0.003$) than control at 16 weeks. Weight change was correlated with MR usage and completion of coaching support calls.



CONCLUSIONS:

Both structured commercial programs were more efficacious than a self-directed, reduced-calorie diet for weight loss and other anthropometric measures. Evidence-based commercial programs can be an important tool to help adults with overweight and obesity lose clinically relevant amounts of weight.

REFERENCE:

Arterburn L.M., Coleman C.D., Kiel J., Kelley K., Mantilla L., Frye N., Sanoshy K., Cook C.M. (2019). Randomized Controlled Trial Assessing Two Commercial Weight Loss Programs in Adults with Overweight or Obesity. *Obes Sci Pract*, 5(1):3-14. doi: doi.org/10.1002/osp4.312.

Shikany (2013)

Randomized Controlled Trial of the Medifast 5 & 1 Plan for Weight loss

JM Shikany^{1,2}, AS Thomas¹, TM Beasley³, CE Lewis^{1,2}, DB Allison^{2,4}

¹Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; ²Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL, USA; ³Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA; ⁴Dean's Office, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.

PURPOSE/OBJECTIVE:

The Medifast 5 & 1 Plan (MD) is a portion-controlled, nutritionally-balanced, low-fat weight-loss plan. We studied the effects of MD compared with a reduced-energy, food-based diet (FB) on body weight, waist circumference, fat mass and other measures in adults.

METHODS/DESIGN:

We conducted a two-parallel-arm, randomized, controlled trial comparing MD to FB over 52 weeks. A total of 120 men and women aged 19–65 years with BMI ≥ 35 and ≤ 50 kg/m² were randomized to MD (n=60) or FB (n=60). Follow-up included a 26-week weight-loss phase and 26-week weight-maintenance phase. Anthropometric, body composition, biochemical and appetite/satiety measures were performed at baseline and at 26 and 52 weeks. An intention-to-treat, linear mixed models analysis was the primary analysis.

RESULTS:

Fifty MD subjects (83.3%) and 45 FB subjects (75.0%) completed the study on assigned treatment. At 26 weeks, race-adjusted mean weight loss was 7.5 kg in MD subjects vs 3.8 kg in FB subjects ($p=0.0002$ for difference); reduction in waist circumference was 5.7 cm in MD vs 3.7 cm in FB ($p=0.0064$); and fat mass loss was 6.4 kg in MD vs 3.7 kg in FB ($p=0.0011$). At 52 weeks, the corresponding reductions were 4.7 vs 1.9 kg ($p=0.0004$); 5.0 vs 3.6 cm ($p=0.0082$); and 4.1 vs 1.9 kg ($p=0.0019$) in MD and FB subjects, respectively.



CONCLUSIONS:

In obese adults, MD resulted in significantly greater reductions in body weight and fat compared with a FB diet for 1 year after randomization.

REFERENCE:

Shikany J.M., Thomas A.S., Beasley T.M., Lewis C.E., Allison D.B. (2013). Randomized Controlled Trial of the Medifast 5 & 1 Plan for Weight Loss. *Int J Obes (Lond)*, 37(12), 1571-1578. doi: [10.1038/ijo.2013.43](https://doi.org/10.1038/ijo.2013.43).

Coleman (2012)

Use of the Medifast Meal Replacement Program for Weight Loss in Overweight and Obese Clients: A Retrospective Chart Review of Three Medifast Weight Control Centers (MWCC)

C Coleman¹, J Kiel¹, A Hanlon-Mitola², C Sonzone¹, N Fuller¹, LM Davis¹

¹Medifast, Inc., Owings Mills, Maryland, USA; ²Private Practice, Clifton Park, New York, USA.

PURPOSE/OBJECTIVE:

A chart review was performed to evaluate the effectiveness of the Medifast (MD) meal replacement (MR) plan in three Medifast Weight Control Centers (MWCC) on body weight, body composition, and other health measures at 4, 12, 24 weeks, and final weight loss visit.

METHODS/DESIGN:

Charts included adults aged 18-70 (n = 446) with a BMI ≥ 25 kg/m² who attended one of three MWCCs and were following the MD MR program. Data were collected electronically and included weight, systolic and diastolic blood pressure, pulse, lean muscle mass (LMM), body fat mass, % body fat, and abdominal circumference. Compliance measures included attendance at weekly visits, intake of MRs and supplements, food journals, and ketone testing.

RESULTS:

Significant weight loss and % weight loss were achieved at all time points with clinically significant weight loss (>5%) occurring in just 4 weeks. Additionally, significant improvements in body composition were seen at all time points coupled with increases in % total body weight as LMM (% LMM improved by 3.5, 9.8, 16.0, and 13.9%, respectively). Blood pressure and pulse were significantly improved, demonstrating the clinical benefit for clients. Multivariate regression revealed a strong inverse relationship between weight change, % compliance with attendance, and the number of weeks that MRs were taken as recommended as well as a positive association with number of ketone tests.



CONCLUSIONS:

The MD MR plan, combined with the support and accountability available in the MWCC, is an efficacious program that promotes significant weight loss and improvements in body composition. These results reveal significant associations between components of compliance and weight loss, but particularly highlight the importance of attendance, a focus of the MWCC model compared to non-clinic models.

REFERENCE:

Coleman C., Kiel J., Hanlon-Mitola A., Sonzone C., Fuller N., Davis L.M. (2012). Use of the Medifast Meal Replacement Program for Weight Loss in Overweight and Obese Clients: A Retrospective Chart Review of Three Medifast Weight Control Centers (MWCC). *Food and Nutrition Sciences*, 03(10), 1433-1444. doi: <http://dx.doi.org/10.4236/fns.2012.310187>.

Davis (2010)

Efficacy of a Meal Replacement Diet Plan Compared to a Food-based Diet Plan After a Period of Weight Loss and Weight Maintenance: A Randomized Controlled Trial

LM Davis¹, C Coleman¹, J Kiel¹, J Rampolla¹, T Hutchisen¹, L Ford¹, WS Andersen¹, A Hanlon-Mitola²

¹Research & Development, Medifast, Inc., Owings Mills, Maryland, USA; ²Private Practice, Clifton Park, New York, USA.

PURPOSE/OBJECTIVE:

Obesity has reached epidemic proportions in the United States.

It is implicated in the development of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress.

The objective of this study is to examine the effect of Medifast's meal replacement program (MD) on body weight, body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a period of weight loss and weight maintenance compared to an isocaloric, food-based diet (FB).

METHODS/DESIGN:

This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI) between 30 and 50 kg/m², randomly assigned to one of two weight loss programs for 16 weeks and then followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifast's meal replacement program for weight loss and weight maintenance, or a self-selected isocaloric, food-based meal plan.

RESULTS:

Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group (FB) (12.3% vs. 6.7%), and while significantly more weight was regained during weight maintenance on MD versus FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost ≥5% of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety observed between the two groups during the weight loss phase. Significant improvements in body composition were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups experienced improvements in biochemical outcomes and other clinical indicators.



CONCLUSIONS:

Our data suggest that the meal replacement diet plan evaluated was an effective strategy for producing robust initial weight loss and for achieving improvements in a number of health-related parameters during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to underlie our most common chronic diseases.

REFERENCE:

Davis L.M., Coleman C., Kiel J., Rampolla J., Hutchisen T., Ford L., Andersen W., Hanlon-Mitola A. (2010). Efficacy of a Meal Replacement Diet Plan Compared to a Food-based Diet Plan After a Period of Weight Loss and Weight Maintenance: A Randomized Controlled Trial. *Nutr J*, 9, 11. doi: [10.1186/1475-2891-9-11](https://doi.org/10.1186/1475-2891-9-11).



The 4 & 2 & 1 Plan[®]

Coleman (2015)

Effectiveness of a Medifast Meal Replacement Plan on Weight, Body Composition, and Cardiometabolic Risk Factors in Overweight and Obese Adults: A Multicenter Systematic Retrospective Chart Review

CD Coleman¹, JR Kiel¹, AH Mitola², JS Langford¹, KN Davis¹, LM Arterburn¹

¹Department of Scientific and Clinical Affairs, Medifast, Inc., 11445 Cronhill Drive, Owings Mills, MD, United States;

²Independent Consultant, Clifton Park, NY, United States.

PURPOSE/OBJECTIVE:

Recent medical guidelines emphasize the importance of actively treating overweight and obesity with diet and lifestyle intervention to achieve $\geq 5\%$ weight loss in a 6-month period. Commercial programs offer one approach provided there is evidence of their efficacy and safety. This study was conducted to evaluate the effectiveness of the Medifast[®] 4 & 2 & 1 Plan on weight loss, body composition and cardiometabolic risk factors in overweight and obese adults.

METHODS/DESIGN:

A systematic retrospective chart review of 310 overweight and obese clients following the Medifast 4 & 2 & 1 Plan at one of 21 Medifast Weight Control Centers[®] was conducted. Data were recorded electronically and key data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks. Within group paired tests were used to examine changes from baseline in a completers population. Differences between gender and age subgroups were examined using bivariate t-tests and mixed model regression analyses.

RESULTS:

For the primary endpoint at 12 weeks, body weight among completers (n=185) was reduced by a mean of 10.9 ± 5.6 kg (-10.1%, $p < 0.0001$), and at 24 weeks (n=81) mean weight was reduced by 16.0 ± 7.9 kg (-14.3%). At 12 and 24 weeks, 85% and 96% of those remaining on the plan, respectively, had lost $\geq 5\%$ of their baseline body weight. Lean mass was preserved to within 5% of baseline throughout the 24 weeks, and fat mass represented $\geq 80\%$ of the body weight lost from 12 weeks onward. Men, women, seniors (≥ 65 yrs), and non-seniors (< 65 yrs) all had significant weight reductions with preservation of lean mass. Significant improvements in blood pressure, pulse and waist-to-hip ratio were observed. Mean weight regain among the subset who entered a formal maintenance phase was $< 2\%$ during an average follow-up of 34 weeks. The meal plan was well tolerated, and program adherence was $> 85\%$.



CONCLUSIONS:

The 4 & 2 & 1 Plan used at Medifast Weight Control Centers was effective for weight loss, preservation of lean mass and improvement in cardiometabolic risk factors. The plan was generally well tolerated in a broad population of overweight and obese adults. #NCT02150837

REFERENCE:

Coleman, C.D., Kiel, J.R., Mitola A.H., Langford J.S., Davis, K.N., Arterburn, L.M. (2015). Effectiveness of a Medifast Meal Replacement Program on Weight, Body Composition and Cardiometabolic Risk Factors in Overweight and Obese Adults: A Multicenter Systematic Retrospective Chart Review Study. *Nutr J*, 14, 77. doi: [10.1186/s12937-015-0062-8](https://doi.org/10.1186/s12937-015-0062-8).

Beavers (2018)

Effect of an Energy–Restricted, Nutritionally Complete, Higher Protein Meal Plan on Body Composition and Mobility in Older Adults with Obesity: A Randomized Controlled Trial

KM Beavers¹, BA Nesbit¹, JR Kiel², JL Sheedy¹, LM Arterburn², AE Collins¹, SA Ford¹, RM Henderson³, CD Coleman², DP Beavers⁴

¹Department of Health and Exercise Science, Wake Forest University, Winston–Salem, North Carolina; ²Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland; ³Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Winston–Salem, North Carolina; ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston–Salem, North Carolina.

PURPOSE/OBJECTIVE:

Increasing protein content of the diet might be an effective strategy to preserve muscle mass in older adults undergoing caloric restriction, thereby preserving muscle function.

METHODS/DESIGN:

Ninety–six older adults (70 ± 3.7 years, 74% women, 27% African American) with obesity (35.4 ± 3.3 kg/m²; 47% total body fat) were randomized to a 6–month higher protein (providing 1.2–1.5 g/kg/d) weight loss (WL) program, utilizing the Medifast 4 & 2 & 1 Plan, or to weight stability (WS). Dual–energy x–ray absorptiometry–acquired total body mass and composition, and fast gait speed over 400–m was assessed at baseline, 3, and 6 months.

RESULTS:

At baseline, dual–energy x–ray absorptiometry–acquired total body, fat, and lean masses were 95.9 ± 14.6, 44.6 ± 7.6, and 48.7 ± 9.5 kg, respectively, and 400–m gait speed was 1.17 ± 0.20 m/s. Total body mass was significantly reduced in the WL group (–8.17 [–9.56, –6.77] kg) compared to the WS group (–1.16 [–2.59, 0.27] kg), with 87% of total mass lost as fat (WL: –7.1 [–8.1, –6.1] kg; –15.9% change from baseline). A differential treatment effect was not observed for change in lean mass (WL: –0.81 [–1.40, –0.23] kg vs WS: –0.24 [–0.85, 0.36] kg). Four–hundred–meter gait speed was also unchanged from baseline although trends suggest slightly increased gait speed in the WL group [0.01 (–0.02, 0.04) m/s] compared with the WS group [–0.02 (–0.05, 0.01) m/s].



CONCLUSIONS:

Intentional weight loss using a high-protein diet is effective in producing significant total body mass and fat mass loss, while helping preserve lean body mass and mobility, in relatively high-functioning older adults with obesity.

REFERENCE:

Beavers K.M., Nesbit B.A., Kiel J.R., Sheedy J.L., Arterburn L.M., Collins A.E., Ford S.A., Henderson R.M., Coleman C.D., Beavers D.P. (2018). Effect of an Energy–Restricted, Nutritionally Complete, Higher Protein Meal Plan on Body Composition and Mobility in Older Adults with Obesity: A Randomized Controlled Trial. *J Gerontol A Biol Sci Med Sci.* 74(6):929–935. doi: [10.1093/gerona/gly146](https://doi.org/10.1093/gerona/gly146).

Normandin (2018)

Feasibility of Weighted Vest use During a Dietary Weight Loss Intervention and Effects on Body Composition and Physical Function in Older Adults

E Normandin¹, D Yow¹, C Crotts¹, J Kiel², KM Beavers³, BJ Nicklas^{1,3}

¹Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston–Salem, NC 27157, USA; ²Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD 21202, USA; ³Department of Health and Exercise Science, Wake Forest University, Winston–Salem, NC 27109, USA.

PURPOSE/OBJECTIVE:

Background: While intentional weight loss in older adults with obesity yields clinically important health benefits there is a need to minimize the negative effects of weight loss on concomitant loss of muscle mass and strength. Data show wearing weighted vests during exercise improves lean mass and lower extremity strength, however the efficacy of wearing a weighted vest during a period of weight loss to mitigate muscle and strength loss is not known.

Objectives: This study examined the feasibility of daily weighted vest use during a dietary weight loss intervention, and examined effects of vest use on body composition and physical function in well-functioning older adults with obesity.

METHODS/DESIGN:

Design: Randomized, controlled pilot study.

Setting: Wake Forest Baptist Medical Center in Winston–Salem, NC.

Participants: 37 older (age=65–79 years), obese (BMI=30–40 kg/m²) sedentary men and women.

Interventions: 22-week behavioral diet intervention (targeting 10% weight loss, 1100–1300 kcals/day with (Diet+Vest; n=20) or without (Diet; n=17) weighted vest use (goal of 10 hours/day with weight added weekly according to individual loss of body mass).

Measurements: Body composition by dual-energy x-ray absorptiometry and measures of physical function, mobility, and muscle strength/power.

RESULTS:

Average weighted vest use was 6.7 ± 2.2 hours/day and the vest-wear goal of 10 hrs/day was achieved for 67 ± 22% of total intervention days. Five participants reported adverse events from wearing the vest (all back pain or soreness). Both groups lost a similar amount of weight (Diet= -11.2 ± 4.4 kg; Diet+Vest= -11.0 ± 6.3 kg; p<0.001), with no differences between groups (p=0.25). Fat mass, lean mass, and % body fat decreased significantly (p<0.0001), with no differences between groups. Compared to Diet+Vest, the Diet intervention resulted in greater decreases in leg power (p<0.02), with no other between group differences in physical function.



CONCLUSIONS:

This pilot study showed that vest use during dietary weight loss is feasible and safe in well-functioning older adults with obesity. Larger studies are needed to definitively determine whether external replacement of lost weight during caloric restriction may preserve lower extremity muscle strength and power.

REFERENCE:

Normandin E., Yow D., Crotts C., Kiel J., Beavers K.M., Nicklas B.J. (2018). Feasibility of Weighted Vest Use During a Dietary Weight Loss Intervention and Effects on Body Composition and Physical Function in Older Adults. *J of Frailty & Aging*; 2018;7(3):198–203. doi: [10.14283/jfa.2018.17](https://doi.org/10.14283/jfa.2018.17).

Dearborn (2023)

Partial Meal Replacement for Weight Loss After Stroke: Results of a Pilot Clinical Trial

JL Dearborn Tomazos¹, CM Viscoli², H Amin³, LJ Lovelett⁴, J Rivera², Anum Gull¹, WN Kernan²

¹Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; ²Department of Medicine, Yale University School of Medicine, New Haven, CT, USA; ³Department of Neurology, Yale University School of Medicine, New Haven, CT, USA; ⁴Department of Speech Language Pathology, Yale New Haven Hospital, New Haven, CT, USA.

PURPOSE/OBJECTIVE:

Over half of patients with acute ischemic stroke are overweight or obese as defined by a body mass index (BMI) ≥ 25 kg/m². Professional and government agencies recommend weight management for these persons to improve risk factors for cardiovascular disease, including hypertension, dyslipidemia, vascular inflammation, and diabetes. However, approaches to weight loss have not been adequately tested specifically in patients with stroke. In anticipation of a larger trial with vascular or functional outcomes, we tested the feasibility and safety of a 12-week partial meal replacement (PMR) intervention for weight loss in overweight or obese patients with a recent ischemic stroke.

METHODS/DESIGN:

This randomized open-label trial enrolled participants from December 2019 to February 2021 (with hiatus from March to August 2020 due to COVID-19 pandemic restrictions on research). Eligible patients had a recent ischemic stroke and BMI 27–49.9 kg/m². Patients were randomized to a PMR diet (OPTAVIA Optimal Weight 4 & 2 & 1 Plan[®]) plus standard care (SC) or SC alone. The PMR diet consisted of four meal replacements supplied to participants, two meals with lean protein and vegetables (self-prepared or supplied), and a healthy snack (also self-prepared or supplied). The PMR diet provided 1,100–1,300 calories per day. SC consisted of one instructional session on a healthy diet. Co-primary outcomes were $\geq 5\%$ weight loss at 12 weeks and to identify barriers to successful weight loss among participants assigned to PMR. Safety outcomes included hospitalization, falls, pneumonia, or hypoglycemia requiring treatment by self or others. Due to the COVID-19 pandemic, study visits after August 2020 were by remote communication.

RESULTS:

We enrolled 38 patients from two institutions. Two patients in each arm were lost and could not be included in outcome analyses. At 12 weeks, 9/17 patients in the PMR group and 2/17 patients in the SC group achieved $\geq 5\%$ weight loss (52.9% vs. 11.9%; Fisher's exact $p=0.03$). Mean percent weight change in the PMR group was -3.0% (SD 13.7) and -2.6% (SD 3.4) in the SC group (Wilcoxon rank-sum $p=0.17$). No adverse events were attributed to study participation. Some participants had difficulty completing home monitoring of weight. In the PMR group, participants reported that food cravings and dislike for some food products were barriers to weight loss.



CONCLUSIONS:

A PMR diet after ischemic stroke is feasible, safe, and effective for weight loss. In future trials, in-person or improved remote outcome monitoring may reduce anthropometric data variation.

REFERENCE:

Dearborn Tomazos J., Viscoli C., Amin H., Lovelett L.J., Rivera J., Gull A., Kernan WN. (2024). Partial Meal Replacement for Weight Loss after Stroke: Results of a Pilot Clinical Trial. *Cerebrovasc Dis.* 2024;53(1):54-61. doi: [10.1159/000530996](https://doi.org/10.1159/000530996).

Justice (2024)

Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the Senescence-Associated Secretome in Middle-Aged and Older Adults with Obesity and Prediabetes in an 18-Week Randomized Controlled Trial

JN Justice^{1,2}, XI Leng^{1,3}, NK LeBrasseur^{4,5}, T Tchkonja^{4,6}, JL Kirkland^{6,7}, N Mitin⁸, Y Liu⁹, SB Kritchevsky^{1,2}, BJ Nicklas^{1,2}, J Ding^{1,2}

¹Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; ²Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; ³Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; ⁴Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA; ⁵Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA; ⁶Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; ⁷Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA; ⁸Sapere Bio, Triangle Research Park, North Carolina, USA; ⁹Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

PURPOSE/OBJECTIVE:

Cellular senescence is a biological aging process that is exacerbated by obesity and leads to inflammation and age and obesogenic-driven chronic diseases including type 2 diabetes. Caloric restriction (CR) may improve metabolic function in part by reducing cellular senescence and the pro-inflammatory senescence-associated phenotype (SASP).

METHODS/DESIGN:

We conducted an ancillary investigation of an 18-week randomized controlled trial (RCT) of CR (n=31) or Control (n=27) in 58 middle-aged/older adults (57.6 ± 5.8 years; 75% Women) with obesity and prediabetes. We measured mRNA expression of select senescence and apoptosis genes in blood CD3+ T cells (qRT-PCR) and a panel of 25 plasma SASP proteins (Luminex/multiplex; ELISA).

RESULTS:

Participants randomized to CR lost -10.8 ± 0.9 kg (-11.3% ± 5.4%) over 18 weeks compared with +0.5 ± 0.9 kg (+0.03% ± 3.5%) in Control group. T-cell expression of senescence biomarkers, p16INK4a and p21CIP1/WAF1, and apoptosis markers, BCL2L1 and BAK1, was not different between CR and Control groups in age, race, and sex-adjusted mixed models (p>.05, all). Iterative principal axis factor analysis was used to develop composite SASP Factors, and the Factors comprising TNFR1, TNFR2, uPAR, MMP1, GDF15, OPN, Fas, and MPO were significantly altered with CR intervention (age, sex, race-adjusted mixed model time × treatment F = 4.17, p≤.05) and associated with the degree of weight loss (R² = 0.12, p≤.05).



CONCLUSIONS:

Our study provides evidence from an RCT that specific circulating biomarkers of senescent cell burden are changed by CR in middle-aged and older adults with obesity and prediabetes. Future studies compare tissue and circulating levels of p16INK4a and pro-inflammatory SASP biomarkers in other populations, and interventions.

REFERENCE:

Justice J.N., Leng X.I., LeBrasseur N.K., Tchkonja T., Kirkland J.L., Mitin N., Liu Y., Kritchevsky S.B., Nicklas B.J., Ding J. (2024). Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the Senescence-Associated Secretome in Middle-Aged and Older Adults With Obesity and Prediabetes in an 18-Week Randomized Controlled Trial. *J Gerontol A Biol Sci Med Sci.* 2024;79(1). doi: [10.1093/gerona/glad214](https://doi.org/10.1093/gerona/glad214).



The 5 & 2 & 2 Plan[®]

Kiel (2015)

The Effectiveness of a Partial Meal Replacement Program in Extremely Obese Individuals: A Systematic Retrospective Chart Review of Medifast Weight Control Centers

JR Kiel¹, CD Coleman¹, AH Mitola², JS Langford¹, KN Davis¹, LM Arterburn¹

¹Department of Scientific & Clinical Affairs, Medifast, Inc., 11445 Cronhill Drive, Owings Mills, MD, USA;

²Independent Consultant, Clifton Park, NY, USA.

PURPOSE/OBJECTIVE:

Extreme obesity is associated with elevated risks of morbidities and mortality, and the prevalence of this condition has been rising. Lifestyle interventions are the cornerstone of all treatment options, yet relatively few studies have assessed the effectiveness of commercial programs for attaining clinically meaningful weight loss ($\geq 5\%$) in this population. The purpose of this study was to evaluate the effectiveness of the Medifast 5 & 2 & 2 Plan[®] administered along with counseling in obese adults, a majority of whom were extremely obese.

METHODS/DESIGN:

We conducted a systematic retrospective chart review of 62 obese clients from 17 Medifast Weight Control Centers[®] (MWCCs). Weight, body composition and cardiometabolic risk factor data were abstracted through 24 weeks. Data were recorded electronically, and key data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks, assessed using Wilcoxon signed rank tests.

RESULTS:

The population consisted of 57% men, and 82% had a body mass index of ≥ 40 kg/m². Mean body weight among completers was reduced by 12.9 ± 7.1 kg (-8.6%, n=37) at the 12-week primary endpoint and by 19.3 ± 11.4 kg (-12.5%, n=17) at 24 weeks (p<0.0001). At 12 and 24 weeks, 76% and 88% of those remaining on the plan, respectively, had lost $\geq 5\%$ of their baseline body weight. Fat mass accounted for a majority (68-80%) of the weight lost, resulting in improvements in body composition. Significant improvements in blood pressure and central adiposity were also observed. Program adherence was >80%, and the meal plan was well-tolerated.



CONCLUSIONS:

The 5 & 2 & 2 Plan used at MWCCs was effective for achieving clinically meaningful weight loss and improving cardiometabolic risk factors in a population of extremely obese individuals. This lifestyle program represents a viable first line approach for meeting treatment goals in extremely obese adults. #NCT02150837.

REFERENCE:

Kiel J.R., Coleman C.D., Mitola A.H., Langford J.S., Davis K.N., Arterburn L.M. (2015). The Effectiveness of a Partial Meal Replacement Program in Extremely Obese Individuals: A Systematic Retrospective Chart Review of Medifast Weight Control Centers. *J Obes Weight Loss Ther*, S5:007. doi: <http://dx.doi.org/10.4172/2165-7904.S5-007>.

Hamilton-Reeves (2020)

Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer – A Pilot Study

JM Hamilton-Reeves^{1,2}, CN Johnson¹, LK Hand², MD Bechtel¹, HL Robertson¹, C Michel¹, M Metcalf¹, P Chalise³, NJ Mahan², M Mirza¹, EK Lee¹, DK Sullivan², JR Klemp⁴, CA Beforte⁵, WP Parker¹, HD Gibbs², W Demark-Wahnefried⁶, JB Thrasher¹

¹Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA; ²Department of Dietetics & Nutrition, University of Kansas Medical Center, Kansas City, Kansas, USA; ³Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas, USA; ⁴Breast Cancer Prevention Center, University of Kansas Medical Center, Westwood, Kansas, USA; ⁵Department of Preventative Medicine and Public Health, University of Kansas Medical Center, Kansas City, Kansas, USA; ⁶Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.

PURPOSE/OBJECTIVE:

Overweight men with prostate cancer are more likely to suffer from recurrence and death following prostatectomy compared with healthy weight men. This study tested the feasibility of delivering a comprehensive program to foster weight loss before and weight maintenance after surgery in overweight men with localized prostate cancer.

METHODS/DESIGN:

Twenty overweight men scheduled for prostatectomy elected either the intervention (n=15) or the nonintervention (n=5). Anthropometrics, biomarkers, diet quality, nutrition literacy, quality of life, and long-term follow-up were assessed in both groups.

RESULTS:

The intervention led to 5.55 kg of weight loss including 3.88 kg of fat loss from baseline to surgery (mean=8.3 weeks). The intervention significantly increased fiber, protein, fruit, nut, and vegetable intake; and decreased trans fats intake during weight loss. The intervention significantly reduced insulin, C-peptide, systolic blood pressure, leptin:adiponectin ratio, and visceral adiposity compared to the nonintervention. Post-surgically, weight loss was maintained. Changes in lipid profiles, nutrition literacy, and follow-up were not statistically significant in either group.



CONCLUSIONS:

Significant weight loss ($\geq 5\%$) is feasible with a coaching intervention in overweight men preparing for prostatectomy and is associated with favorable cardiometabolic effects. This study is registered under [NCT02252484](https://clinicaltrials.gov/ct2/show/study/NCT02252484).

REFERENCE:

Hamilton-Reeves, J. M., Johnson, C. N., Hand, L. K., Bechtel, M. D., Robertson, H. L., Michel, C., Metcalf, M., Chalise, P., Mahan, N. J., Mirza, M., Lee, E. K., Sullivan, D. K., Klemp, J. R., Befort, C. A., Parker, W. P., Gibbs, H. D., Demark-Wahnefried, W., & Thrasher, J. B. (2020). Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. *Nutr Cancer*, 1-16. <https://doi.org/10.1080/01635581.2020.1856890>.

Dimachkie (2021)

Exploration of Biomarkers from a Pilot Weight Management Study for Men Undergoing Radical Prostatectomy

MD Dimachkie¹, MD Bechtel¹, HL Robertson¹, C Michel¹, EK Lee¹, DK Sullivan², P Chalise³, JB Thrasher¹, WP Parker¹, AK Godwin⁴, HB Pathak⁴, J DiGiovanni⁵, N Shivappa^{6,7,8}, JR Hébert^{6,7,8}, JM Hamilton-Reeves^{1,2}

¹Department of Urology, University of Kansas Medical Center, Kansas City, KS; ²Department of Dietetics & Nutrition, University of Kansas Medical Center, Kansas City, KS; ³Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS; ⁴Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS; ⁵Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX; ⁶Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208; ⁷Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC; ⁸Connecting Health Innovations LLC, Columbia, SC.

PURPOSE/OBJECTIVE:

Several biologic mechanisms, including inflammation and immune changes, have been proposed to explain the role of obesity in prostate cancer (CaP) progression. Compared to men of a healthy weight, overweight and obese men are more likely to have CaP recurrence post-prostatectomy. Obesity is related to inflammation and immune dysregulation; thus, weight loss may be an avenue to reduce inflammation and reverse these immune processes. This study explores the reversibility of the biological mechanisms through intentional weight loss using a comprehensive weight management program in men undergoing prostatectomy. Outcomes include blood and tissue biomarkers, microtumor environment gene expression, inflammation markers and Dietary Inflammatory Index (DII) scores.

METHODS/DESIGN:

Twenty overweight men undergoing prostatectomy participated in this study. Fifteen men chose the intervention and 5 men chose the nonintervention group. The intervention consisted of a comprehensive weight loss program prior to prostatectomy and a weight maintenance program following surgery. Prostate tissue samples were obtained from diagnostic biopsies before the intervention and prostatectomy samples after weight loss. Blood samples and diet records were collected at baseline, pre-surgery after weight loss and at study end after weight maintenance. Immunohistochemistry and NanoString analysis were used to analyze the tissue samples. Flow cytometry was used to assess circulating immune markers. Inflammation markers were measured using Luminex panels.

RESULTS:

The intervention group lost >5% body weight prior to surgery. DII scores improved during the weight loss intervention from baseline to pre-surgery (P=0.002); and between group differences were significant (P=0.02). DII scores were not associated with IL-6 nor hsCRP. In the intervention, CXCL12, CXCR7, and CXCR4 (C-X-C motif chemokine ligand/receptor) and Ki67 expression decreased in the prostate tissue from biopsy to surgery (P=0.06), yet plasma CXCL12 increased during the same timeframe (P=0.009). The downregulation of several genes (FDR<0.001) was observed in the intervention compared to the non-intervention. Changes in immune cells were not significant in either group.



CONCLUSIONS:

This feasibility study demonstrates that in overweight men with localized CaP, weight loss alters blood, and tissue biomarkers, as well as tumor gene expression. More research is needed to determine the biological and clinical significance of these findings.

REFERENCE:

Dimachkie, M. D., Bechtel, M. D., Robertson, H. L., Michel, C., Lee, E. K., Sullivan, D. K., Chalise, P., Thrasher, J. B., Parker, W. P., Godwin, A. K., Pathak, H. B., DiGiovanni, J., Shivappa, N., Hébert, J. R., & Hamilton-Reeves, J. M. (2021). Exploration of biomarkers from a pilot weight management study for men undergoing radical prostatectomy. *Urol Oncol.* 2021;39(8):495.e7-495.e15. <https://doi.org/10.1016/j.rolonc.2021.01.010>.

Betchel (2024)

Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression

MD Bechtel¹, C Michel¹, P Srinivasan¹, P Chalise², WP Parker¹, M Mirza¹, B Thrasher¹, HD Gibbs³, J DiGiovanni^{4,5,6}, J Hamilton-Reeves¹

¹Department of Urology, University of Kansas Medical Center, Kansas City, Kansas; ²Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas; ³Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas; ⁴Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas; ⁵Center for Molecular Carcinogenesis and Toxicology, The University of Texas at Austin, Austin, Texas; ⁶Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin, Austin, Texas Pathology, Yale New Haven Hospital, New Haven, CT, USA.

PURPOSE/OBJECTIVE:

Excess body and visceral fat increase the risk of death from prostate cancer (PCa). This phase II study aimed to test whether weight reduction by >5% total body weight counteracts obesity-driven PCa biomarkers.

METHODS/DESIGN:

Forty men scheduled for prostatectomy were randomized into intervention (n = 20) or control (n = 20) arms. Intervention participants followed a weight management program for 4 to 16 weeks before and 6 months after surgery. Control participants received standardized educational materials. All participants attended visits at baseline, 1 week before surgery, and 6 months after surgery. Circulating immune cells, cytokines, and chemokines were evaluated. Weight loss, body composition/distribution, quality of life, and nutrition literacy were assessed. Prostate tissue samples obtained from biopsy and surgery were analyzed.

RESULTS:

From baseline to surgery (mean = 5 weeks), the intervention group achieved 5.5% of weight loss (95% CI, 4%-7%). Compared to the control, the intervention also reduced insulin, total cholesterol, LDL cholesterol, leptin, leptin:adiponectin ratio, and visceral adipose tissue. The intervention group had reduced c-peptide, plasminogen-activator-inhibitor-1, and T cell count from baseline to surgery. Myeloid-derived suppressor cells were not statistically different by group. Intervention group anthropometrics improved, including visceral and overall fat loss. No prostate tissue markers changed significantly. Quality of life measures of general and emotional health improved in the intervention group. The intervention group maintained or kept losing to a net loss of 11% initial body weight (95% CI, 8%-14%) at the study end.



CONCLUSIONS:

Our study demonstrated improvements in body composition, PCa biomarkers, and quality of life with a weight management intervention.

REFERENCE:

Bechtel M.D., Michel C., Srinivasan P., Chalise P., Parker W.P., Mirza M., Thrasher B., Gibbs H.D., DiGiovanni J., Hamilton-Reeves J. (2024). Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression. *J Urol.* 2024 Apr 1; 211(4):552–62. Available from: <https://doi.org/10.1097/JU.0000000000003849>.



Diabetes

Coleman (2017)

Comparative Effectiveness of a Portion-Controlled Meal Replacement Program for Weight Loss in Adults With and Without Diabetes/High Blood Sugar

CD Coleman¹, JR Kiel¹, AH Mitola², LM Arterburn¹

¹Department of Scientific & Clinical Affairs, Medifast, Inc., 11445 Cronhill Drive, Owings Mills, MD, USA; ²Independent Consultant, Clifton Park, NY, USA.

PURPOSE/OBJECTIVE:

Individuals with type 2 diabetes (DM2) may be less successful at achieving therapeutic weight loss than their counterparts without diabetes. This study compares weight loss in a cohort of adults with DM2 or high blood sugar (D/HBS) to a cohort of adults without D/HBS. All were overweight/obese and following a reduced or low-calorie commercial weight-loss program incorporating meal replacements (MRs) and one-on-one behavioral support.

METHODS/DESIGN:

Demographic, weight, body composition, anthropometric, pulse and blood pressure data were collected as part of systematic retrospective chart review studies. Differences between cohorts by D/HBS status were analyzed using Mann–Whitney U-tests and mixed model regression.

RESULTS:

A total of 816 charts were included (125 with self-reported D/HBS). The cohort with D/HBS had more males (40.8 vs 25.6%), higher BMI (39.0 vs 36.3 kg/m²) and was older (56 vs 48 years). Among clients continuing on program, the cohorts with and without D/HBS lost, on average, 5.6 vs 5.8 kg (NS) (5.0 vs 5.6%; p=0.005) of baseline weight at 4 weeks, 11.0 vs 11.6 kg (NS) (9.9 vs 11.1%; p=0.027) at 12 weeks and 16.3 vs 17.1 kg (13.9 vs 15.7%; NS) at 24 weeks, respectively. In a mixed model regression controlling for baseline weight, gender and meal plan, and an intention-to-treat analysis, there was no significant difference in weight loss between the cohorts at any time point. Over 70% in both cohorts lost ≥5% of their baseline weight by the final visit on their originally assigned meal plan. Both cohorts had significant reductions from baseline in body fat, blood pressure, pulse and abdominal circumference.



CONCLUSIONS:

Adults who were overweight/obese and with D/HBS following a commercial weight-loss program incorporating MRs and one-on-one behavioral support achieved therapeutic weight loss. The program was equally effective for weight loss and reductions in cardiometabolic risk factors among adults with and without D/HBS.

REFERENCE:

Coleman C.D., Kiel J.R., Mitola A.H., Arterburn L.M. (2017). Comparative Effectiveness of a Portion-Controlled Meal Replacement Program for Weight Loss in Adults With and Without Diabetes/High Blood Sugar. *Nutr Diabetes*; 7(7):e284. doi: [10.1038/nutd.2017.32](https://doi.org/10.1038/nutd.2017.32).

Cheskin (2008)

Efficacy of Meal Replacements Versus a Standard Food-Based Diet for Weight Loss in Type 2 Diabetes: A Controlled Clinical Trial

LJ Cheskin, AM Mitchell, AD Jhaveri, AH Mitola, LM Davis, RA Lewis, MA Yep, TW Lycan

From the Johns Hopkins Bloomberg School of Public Health, Department of International Health, Center for Human Nutrition, Baltimore, Maryland.

PURPOSE/OBJECTIVE:

The purpose of this study is to compare the efficacy of a portion-controlled meal-replacement diet (PCD) to a standard diet (SD) based on recommendations by the American Diabetes Association in achieving and maintaining weight loss among obese participants with type 2 diabetes.

METHODS/DESIGN:

This study is a university-based, controlled clinical trial. Participants were 119 men and women with diabetes with a body mass index between 25 and 40 kg/m², assigned randomly to one of two 34-week, 75% of predicted energy need diets (portion controlled or standard, self-selected, food based) and then followed by 1-year of maintenance.

RESULTS:

Using intention-to-treat (ITT) analyses, weight loss at 34 weeks and weight maintenance at 86 weeks was significantly better on PCD versus SD. Approximately 40% of the PCD participants lost ≥5% of their initial weight compared with 12% of those on the SD. Significant improvements in biochemical and metabolic measures were observed at 34 weeks in both groups. The retention rate and self-reported ease of adherence in the PCD group were significantly higher throughout the study.




CONCLUSIONS:

A diet using portion-controlled meal replacements yielded significantly greater initial weight loss and less regain after 1 year of maintenance than a standard, self-selected, food-based diet. As PCDs may help obese patients with type 2 diabetes adhere to a weight control program, diabetes educators may consider recommending them as part of a comprehensive approach to weight control.

REFERENCE:

Cheskin L.J., Mitchell A.M., Jhaveri A.D., Mitola A.H., Davis L.M., Lewis R.A., Yep, M.A., Lycan T.W. (2008). Efficacy of Meal Replacements Versus a Standard Food-Based Diet for Weight Loss in Type 2 Diabetes: A Controlled Clinical Trial. *Diabetes Educ*, 34(1), 118-127. doi: 10.1177/0145721707312463.



**Healthy Habits & Early
Indicators of Success**

Coleman (2022)

Healthy Habits Associated with Successful Weight Loss Maintenance on a Commercial Program: Learnings from a Research Survey

Coleman CD¹, J Kiel¹, C LaCalamita², N Frye¹, L Provelengios¹

¹Department of Scientific & Clinical Affairs, Medifast, Inc., Baltimore, MD, USA; ²Department of Planning & Strategy, Medifast, Inc., Baltimore, MD, USA.

PURPOSE/OBJECTIVE:

Maintenance of lost weight is a challenging aspect of weight management, therefore, an online survey of OPTAVIA (“the Program”) coaches and clients was conducted to understand the habits of successful maintainers.

METHODS/DESIGN:

Coaches and clients who lost $\geq 10\%$ body weight on the Program, had been trying to maintain their weight loss for ≥ 1 year, and maintained $>75\%$ of their weight loss during that time were identified. Mean \pm SD were calculated for continuous variables and categorical variables were quantified using frequencies and percentages.

RESULTS:

The analysis included 590 respondents (342 coaches, 248 clients; 84% female, 52.6 ± 11.9 years). Average weight loss was $23.7\% \pm 8.6\%$; average time in maintenance was 24.5 ± 15.8 months. The most common maintenance strategies included self-monitoring, leveraging habits learned during weight loss, food-related strategies, physical activity, establishing a healthy environment, and becoming a coach. Coaches identified several beneficial factors: higher accountability, increased self-awareness, paying it forward, aligning maintenance with their identity as a coach, being a role model, and engagement with the Program.



CONCLUSIONS:

Successful coaches and clients use behaviors consistent with existing literature combined with several unique to the Program. The novel insights from this research rest primarily on the strategy of becoming a coach to help maintain weight loss.

REFERENCE:

Coleman C., Kiel J., LaCalamita C., Frye N., Provelengios, L. (2022). Healthy Habits Associated with Successful Weight Loss Maintenance on a Commercial Program: Learnings from a Research Survey. *Food and Nutrition Sciences*, 13, 453-462. <https://doi.org/10.4236/fns.2022.135033>.

Coleman (2023)

Importance of Early Weight Loss and Other Predictors of Lower Weight Loss in a Commercial Program: A Secondary Data Analysis

CD Coleman¹, JR Kiel¹, LL Guarneiri², M Bell², ML Wilcox², KC Maki^{2,3}, JL Unick⁴, SS Jonnalagadda¹

¹Department of Scientific and Clinical Affairs, Medifast, Inc. Baltimore, Maryland, USA; ²Midwest Biomedical Research, Addison, Illinois, USA;

³Indiana University Department of Applied Health Science, School of Public Health-Bloomington, Bloomington, Indiana, USA; ⁴The Miriam Hospital's Weight Control and Diabetes Research Center, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.

PURPOSE/OBJECTIVE:

There is substantial inter-individual variability in response to weight loss interventions and emerging evidence suggests that weight loss during the early weeks of an intervention may be predictive of longer-term weight loss. This secondary analysis of data from a commercial program therefore examined 1) the associations between early weight loss (i.e., week 4) with final visit weight loss and duration on the program, and 2) other predictors of lower weight loss at final visit.

METHODS/DESIGN:

Client charts of adults with overweight or obesity (N=748) were analyzed. Clients were stratified into categories of weight loss at the week 4 (< and ≥2%, 3% and 4%) and final visits (< and ≥5% and 10%). Multivariate logistic regression was used to assess predictors of <5% and <10% final visit weight loss.

RESULTS:

The odds ratios for losing <5% or <10% of weight at the final visit were higher (49.0 (95% CI: 13.84, 173.63) and 20.1 (95% CI: 6.96, 58.06)) for clients who lost <2% or <3% compared to those who lost ≥2% or ≥3% at week 4. Other predictors of not losing a clinically relevant amount of weight included female sex, use of higher calorie meal plans and shorter time in the program, among others. Those who lost ≥2% at week 4 also had a significantly greater percent program completion (109.2 ± 75.2% vs. 82.3 ± 82.4, p<0.01) compared with those who did not meet the 2% threshold.



CONCLUSIONS:

Lower 4-week weight loss was identified as a strong predictor of not losing a clinically relevant amount of weight. These results may be useful for the early identification of individuals who can be targeted for additional counseling and support to aid in attaining weight loss goals.

REFERENCE:

Coleman C.D., Kiel J.R., Guarneiri L.L., Bell M., Wilcox M.L., Maki K.C., Unick J.L., Jonnalagadda S.S. (2023). Importance of Early Weight Loss and Other Predictors of Lower Weight Loss in a Commercial Program: A Secondary Data Analysis. *Obes Sci Pract.* 2023; 1-9. <https://doi.org/10.1002/osp4.724>.

Vernarelli (2024)

Health Behaviors Predicting Risk of Obesity in US Adults: What Does a Healthy Lifestyle Look Like?

JA Vernarelli¹, JR Kiel², CD Coleman², Satya S. Jonnalagadda²

¹Department of Public Health, Sacred Heart University, Fairfield, CT, USA; ²Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, USA.

PURPOSE/OBJECTIVE:

The purpose of this study was to examine the association between lifestyle factors and body weight in a nationally representative sample of US adults and to evaluate the association between a novel “Healthy Habits Composite Score (HHCS)” and risk of obesity.

METHODS/DESIGN:

This cross-sectional study included data from 4870 adults who participated in the 2017–2018 National Health and Nutrition Examination Survey (NHANES). The HHCS was developed based on 4 factors: diet, physical activity, sedentary time, and sleep, all of which were measured during the NHANES. A “healthy lifestyle” was defined as meeting ≥ 3 of the 4 established criteria. Data analysis was conducted using SAS 9.4 and procedures to account for the complex survey design. All models were adjusted for age, sex, race, household income, and education.

RESULTS:

Adults with obesity had significantly lower dietary quality (48.8 ± 0.6 vs. 53.2 ± 0.9) and reported significantly more sedentary time (~ 1 h more; 356.3 ± 7.0 vs. 301.4 ± 8.3 min) than lean adults, both $p < 0.001$. Achieving a healthy lifestyle based on the HHCS was associated with nearly double the odds of having a healthy body weight (OR 1.9, $p < 0.001$).



CONCLUSIONS:

Following a lifestyle focused on healthy habits (diet quality, physical activity, limited sedentary time, and sleep) was strongly associated with a decreased risk of obesity: an individual who achieved three or more healthy habits had nearly twice the odds of having a healthy body weight. Therefore, comprehensive interventions that address and promote a wide range of healthy habits may be most effective for lowering obesity risk.

REFERENCE:

Vernarelli J.A., Kiel J.R., Coleman C.D., Jonnalagadda S.S. (2024). Health Behaviors Predicting Risk of Obesity in US adults: What Does a Healthy Lifestyle Look Like? *Obes Sci Pract.* 2024 Jul 17;10(4):e781. doi: [10.1002/osp4.781](https://doi.org/10.1002/osp4.781).

Miller (2021)

Current Practices and Desired Features Associated with Recipes on a Commercial Weight Management Program

A Miller¹, J Christman¹, C LaCalamita²

¹Medifast, Inc., Department of Scientific & Clinical Affairs; ²Medifast, Inc., Department of Strategy and Business Development, 100 International Drive, Baltimore, MD 21202.

PURPOSE/OBJECTIVE:

An online survey of real-world OPTAVIA Coaches and Clients was conducted to understand the use and desired features of OPTAVIA recipes as part of the OPTAVIA program, a holistic commercial weight management program that includes support from a Coach. The survey targeted recipe use, improvements, and optimization for Client acquisition and retention.

METHODS/DESIGN:

A randomized sample of 15,000 Clients and 7,000 Coaches with purchase activity in the past 6 months, plus 7 Coach Leaders, were sent an electronic survey invitation. 1296 respondents (631 Coaches; 665 Clients) were included in the analysis. All data was self-reported. Categorical variables were quantified using frequencies and percentages.

RESULTS:

86% of respondents reported using recipes. 66% prepared their meals the day of compared to preparing some (31%) or all (3%) in advance. Most desired recipe features include: <30 minutes of preparation (75%), simple (60%) easy-to-find ingredients (60%) and use a slow cooker/crockpot (46%). Vegan (12%) and vegetarian options/modifications (15%) and sweeter (17%) recipes ranked lowest. Greatest desired improvements include: clear portion sizes (52%), less preparation (43%), grocery list provision (42%) and reducing cook time (38%). Least desired include: detailed nutritional (16%) and recipe ratings (17%). 83% of Coaches use recipes for Client engagement; 75% for acquisition. The greatest recipe-use barriers: too much preparation (20%) and family's dislikes (20%).



CONCLUSIONS:

Developing simple to prepare recipes with clear portion sizes and easy-to-find ingredients that can be used for later meals may optimize recipe use and enhance Coaches' ability to leverage recipe-sharing for both Client engagement and acquisition.

REFERENCE:

This abstract was accepted and presented as a poster at the Academy of Nutrition and Dietetics' Food and Nutrition Conference and Exposition (Virtual) Conference in 2021.

Miller A., Christman J., LaCalamita C. (2021). Current Practices and Desired Features Associated with Recipes on a Commercial Weight Management Program. *J Acad Nutr Diet*, 121(10) PA138. DOI: <https://doi.org/10.1016/j.jand.2021.08.054>.

Davis (2008)

The Effect of Metabolism-Boosting Beverages on 24-hr Energy Expenditure

LM Davis¹, CD Coleman¹, WS Andersen¹, LJ Cheskin²

¹Medifast Inc. Research & Development, 11445 Cronhill Drive, Owings Mills, MD, USA; ²Johns Hopkins Bloomberg School of Public Health, Department of International Health, Division of Human Nutrition, Baltimore, MD, USA.

PURPOSE/OBJECTIVE:

The effect of thermogenic meal replacement beverages (TMRB) containing 90 mg [epigallocatechin gallate] EGCG and 100 mg of caffeine on resting energy expenditure (REE) was tested.

METHODS/DESIGN:

Thirty adults (19 women, 11 men) were stratified into 3 groups: lean (n=10, BMI 21.5 ± 2.1 [kg/m²]); overweight/obese (OW) (n=10, BMI 29.8 ± 2.7); or weight maintainers (WM) (n=10, BMI 28.8 ± 4.0). Following an overnight fast, baseline measurements, including REE via indirect calorimetry, were performed. REE was repeated at 30, 60, 90, and 120 minutes after consuming a TMRB. Appetite was assessed via visual analogue scale at baseline, 30 minutes, and 120 minutes after the TMRB.

RESULTS:

Mean 24-hour REE was increased $5.9 \pm 2.5\%$ overall ($p=0.000$), $5.7 \pm 3.1\%$ among lean subjects ($p=0.0002$), $5.3 \pm 1.4\%$ among OW subjects ($p=0.000$), and $6.8 \pm 2.7\%$ among WM subjects ($p=0.0007$). Appetite was significantly reduced 30 minutes after the TMRB ($p=0.0002$).



CONCLUSIONS:

TMRB appear to be a promising weight control tool.

REFERENCE:

Davis L.M., Coleman C., Andersen W.S., Cheskin L.J. (2008). The Effect of Metabolism-Boosting Beverages on 24-hr Energy Expenditure. *The Open Nutrition Journal*, 2(37-41).



**Obesity Pharmacotherapy &
Non Pharmaceutical Appetite Suppressants**

Grosicki (2025)

Glucagon-Like Peptide-1 Receptor Agonists Discontinuation is Higher in Individuals with Overweight and Obesity Without Type 2 Diabetes

GC Grosicki¹, JG Thomas^{2,3}, NV Dhurandhar⁴, H Lofton⁵, SB Heymsfield⁶, SS Jonnalagadda¹

¹Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland, USA; ²Weight Control and Diabetes Research Center, The Miriam Hospital, Providence, Rhode Island, USA; ³Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA; ⁴Department of Nutritional Sciences, Texas Tech University, Lubbock, Texas, USA; ⁵General Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA; ⁶Pennington Biomedical Research Center, LSU System, Baton Rouge, Louisiana, USA.

PURPOSE/OBJECTIVE:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including mono, dual and triple agonists, are transforming obesity care. Despite the calls for their long-term use, emerging data reveal relatively high discontinuation rates. Understanding why patients discontinue GLP-1 RAs is critical for improving persistence and promoting long-term weight loss maintenance and associated health benefits.

METHODS/DESIGN:

A time-restrained systematic review and meta-analysis of observational real-world studies was conducted to better understand GLP-1 RA discontinuation rates and factors influencing discontinuation with a particular focus on Type 2 Diabetes (T2D) within obesity care. Studies published on or after the U.S. Food and Drug Administration's 2021 approval of new generation GLP-1 RAs for chronic weight management were selected and we specifically focused on one-year discontinuation rates. A random-effects meta-analysis was performed to estimate the pooled one-year GLP-1 RA discontinuation rate across studies. A meta-regression analysis was also conducted to explore the potential impact of the proportion of T2D on GLP-1 RA discontinuation rate. Reasons for discontinuation and associated factors were qualitatively summarized.

RESULTS:

After evaluation of full-text articles that met all the initial criteria (n=111), nine articles were deemed eligible for inclusion. The median sample size of included studies was 5103, and the one-year median discontinuation rate was 50.1%. The pooled one-year discontinuation rate from the random-effects meta-analysis was 48.7%. A meta-regression exploring the association between the proportion of patients with T2D and the one-year discontinuation rate revealed a significant negative association; the adjusted R² was 61.6%.



CONCLUSIONS:

Findings indicate that nearly half of patients who begin a GLP-1 RA will discontinue within a year and the proportion of patients with T2D explained a significant proportion of the variation between studies. To support long-term weight loss maintenance, barriers to continued GLP-1 RA treatment should be addressed through strategies such as patient and health insurer education on the chronicity of obesity, the long-term cost-effectiveness of sustained treatment and the importance of lifelong transformation through the integration of long-term medication use and healthy habits.

REFERENCE:

Glucagon-Like Peptide-1 Receptor Agonists Discontinuation is Higher in Individuals with Overweight and Obesity Without Type 2 Diabetes. (2025). *Diabetes Obes Metab.* 2025;27(3):1597-1600. doi: [10.1111/dom.16151](https://doi.org/10.1111/dom.16151).

Grosicki (2024)

Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications

GJ Grosicki¹, NV Dhurandhar², JL Unick^{3,4}, SM Arent⁵, JG Thomas^{3,4}, H Lofton⁶, MC Shepherd¹, J Kiel¹, C Coleman¹, SS Jonnalagadda¹

¹Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, United States; ²Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, United States; ³The Miriam Hospital Weight Control and Diabetes Research Center, Providence, RI, United States; ⁴Warren Alpert Medical School at Brown University, Providence, RI, United States; ⁵Department of Exercise Science, University of South Carolina, Columbia, SC, United States; ⁶New York University Grossman School of Medicine, New York, NY, United States.

ABSTRACT:

Obesity is a public health crisis, with prevalence rates tripling over the past 60 y. Although lifestyle modifications, such as diet and physical activity, remain the first-line treatments, recent anti-obesity medications (AOMs) have been shown to achieve greater reductions in body weight and fat mass. However, AOMs also reduce fat-free mass, including skeletal muscle, which has been demonstrated to account for 20% to 50% of total weight loss. This can equate to ~6 kg or 10% of total lean mass after 12–18 mo, a loss comparable to a decade of human aging. Despite questions surrounding the clinical relevance of weight loss-induced muscle loss, the importance of adopting lifestyle behaviors such as eating a protein-rich diet and incorporating regular resistance training to support skeletal muscle health, long-term weight loss maintenance, and overall well-being among AOM users should be encouraged. Herein, we provide a rationale for the clinical significance of minimizing weight loss-induced lean mass loss and emphasize the integration of diet and physical activity into AOM clinical care. Owing to a lack of published findings on diet and physical activity supporting skeletal muscle health with AOMs, specifically, we lean on findings from large-scale clinical weight loss and diet and exercise trials to draw evidence-based recommendations for strategies to protect skeletal muscle. We conclude by identifying gaps in the literature and emphasizing the need for future experimental research to optimize skeletal muscle and whole-body health through a balance of pharmacotherapy and healthy habits.

REFERENCE:

Grosicki G.J., Dhurandhar N.V., Unick J.L., Arent S.M., Thomas J.G., Lofton H., Shepherd M.C., Kiel J., Coleman C., Jonnalagadda S.S. (2024). Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications. *Curr Dev Nutr.* 2024;8(11), 2475-2991. <https://doi.org/10.1016/j.cdnut.2024.104486>.

Moldovan (2016)

Effects of a Meal Replacement System Alone or in Combination with Phentermine on Weight Loss and Food Cravings

CP Moldovan^{1*}, AJ Weldon^{2*}, NS Daher³, LE Schneider⁴, DL Bellinger⁵, LS Berk^{3,6}, AC Herme¹, AL Archeiga¹, WL Davis², WR Peters⁷

¹Department of Psychology, School of Behavioral Health; ²Department of Pharmaceutical and Administrative Sciences, School of Pharmacy; ³Department of Allied Health Studies, School of Allied Health Professions; ⁴Department of Nutrition and Dietetics, School of Allied Health Professions; ⁵Department of Pathology and Human Anatomy; ⁶Department of Physical Therapy, School of Allied Health Professions, ⁷Department of Preventative Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA *CPM and AJW contributed equally to this article.

PURPOSE/OBJECTIVE:

To examine the effects of phentermine combined with a meal replacement program on weight loss and food cravings and to investigate the relationship between food cravings and weight loss.

METHODS/DESIGN:

In a 12-week randomized, double-blind, placebo-controlled clinical trial, 77 adults with obesity received either phentermine or placebo. All participants were provided with Medifast® meal replacements, were instructed to follow the Take Shape for Life® Optimal Weight 5&1 Plan for weight loss, and received lifestyle coaching in the Habits of Health program. The Food Craving Inventory and the General Food Cravings State and Trait Questionnaires were used to measure food cravings.

RESULTS:

The phentermine group lost 12.1% of baseline body weight compared to 8.8% in the placebo group. Cravings for all food groups decreased in both groups; however, there was a greater reduction in cravings for fats and sweets in the phentermine group compared with the placebo group. Percent weight loss correlated significantly with reduced total food cravings ($r=0.332$, $p=0.009$), cravings for sweets ($r=0.412$, $p<0.000$), and state food cravings ($r=0.320$, $p=0.007$).



CONCLUSIONS:

Both phentermine combined with a meal replacement program and meal replacements alone significantly reduced body weight and food cravings; however, the addition of phentermine enhanced these effects.

REFERENCE:

Moldovan C.P., Weldon A.J., Daher N.S., Schneider L.E., Bellinger D.L., Berk L.S., Herme A.C., Archeiga A.L., Davis W.L., Peters W.R. (2016). Effects of a Meal Replacement System Alone or in Combination with Phentermine on Weight Loss and Food Cravings. *Obesity*, 2016;24(11):2344-2350. doi: [10.1002/oby.21649](https://doi.org/10.1002/oby.21649).

Haddock (2008)

Effectiveness of Medifast Supplements Combined with Obesity Pharmacotherapy: A Clinical Program Evaluation

CK Haddock¹, WSC Poston¹, JP Foreyt², JJ DiBartolomeo³, PO Warner⁴

¹University of Missouri, Kansas City School of Medicine; ²Baylor College of Medicine; ³Medifast, Inc.; ⁴New Dimensions Medical Group.

PURPOSE/OBJECTIVE:

To evaluate the long-term impact of Medifast meal-replacement supplements (MMRS) combined with appetite suppressant medication (ASM) among participants who received 52 weeks of treatment.

METHODS/DESIGN:

We conducted a systematic program evaluation of weight loss data from a medically-supervised weight control program combining the use of MMRS and ASM. Data were obtained and analyzed from 1,351 patient (BMI ≥ 25) medical charts who had participated for at least 12 weeks of treatment. Outcomes included weight loss (kg) and percent weight loss from baseline at 12, 24, and 52 weeks. Both completers and intention-to-treat (ITT) analyses were conducted. Completers' (i.e., those with complete data for 52 weeks) outcomes were evaluated after stratification for reported adherence to the MMRS and ASM.

RESULTS:

Participants who completed 52 weeks of treatment experienced substantial weight losses at 12 (-9.4 ± 5.7 kg), 24 (-12.0 ± 8.1 kg), and 52 weeks (-12.4 ± 9.2 kg), and all measures were significantly different from baseline weight ($p < 0.001$ for all contrasts) for both true completers ($n=324$) and for ITT analysis ($n=1,351$). Fifty percent of patients remained in the program at 24 weeks and nearly 25% were still participating at one year.



CONCLUSIONS:

This weight loss program using a combination of MMRS and ASM produced significant and sustained weight losses at 52 weeks. Results were better than those typically reported for obesity pharmacotherapy in both short- and long-term studies and also better than those reported for partial meal replacement programs. Program retention at one year was similar to that reported in many controlled drug trials and better than most commercial programs reported in the literature.

REFERENCE:

Haddock C.K., Poston W.S.C., Foreyt J.P., DiBartolomeo J.J., Warner P.O. (2008). Effectiveness of Medifast Supplements Combined with Obesity Pharmacotherapy: A Clinical Program Evaluation. *Eat Weight Disord*, 13(2), 95-101.

Matalon (2000)

An Evaluation of Weight Loss Following a Carbohydrate and Fat Restricted Diet with Appetite Suppressant and Dietary Supplementation

V Matalon¹

¹TLC Healthcare, Inc., Marlton, N.J. USA.

PURPOSE/OBJECTIVE:

This was an open label trial designed to assess the safety and effectiveness of a weight loss regimen consisting of a carbohydrate and fat restricted diet, supplemented with an appetite suppressant, a dietary supplement, and a liquid protein drink.

METHODS/DESIGN:

Forty-seven adult patients were prescribed a carbohydrate and fat restricted diet supplemented with a natural appetite suppressant, a dietary supplement and a liquid protein drink [Medifast]. In addition, patients at risk for gallbladder disease were given ursodiol (Actigall[®]) 300 mg BID. At baseline, evaluations included a history and physical, and measurements of total body weight (lbs), body fat (%), BMI, lean body mass, water weight and blood pressure. Patients were then seen weekly for 6 months. At each weekly visit, total weight, % body fat, BMI, lean body mass, water weight and BP were noted.

RESULTS:

At the end of the study, statistically significant differences from baseline to final value were noted for body weight ($p < 0.001$), percent body fat ($p < 0.001$), BMI ($p < 0.001$), lean body mass ($p = 0.001$), water weight ($p = 0.01$), and both systolic ($p = 0.003$) and diastolic ($p < 0.001$) blood pressure.




CONCLUSIONS:

This dietary regimen showed that a carbohydrate and fat restricted program supplemented by a natural appetite suppressant can lead to progressive weight loss of comparable value to currently prescribed pharmacological agents [at the time of the study]. Patients in this study experienced statistically significant decreases in overall body weight, percent body fat, BMI, lean body mass, total body water and both systolic and diastolic blood pressure.

REFERENCE:

Matalon, V. (2000). An Evaluation of Weight Loss Following a Carbohydrate and Fat Restricted Diet with Appetite Suppressant and Dietary Supplementation. *The Bariatrician*, 10-13.



**Polycystic Ovarian Syndrome
(PMOS)**

Yuh (2011)

Efficacy of a Hypocaloric Weight Management Program in Obese Women with Polycystic Ovarian Syndrome (PCOS)

J Yuh¹, D Debrakeleer¹, W McIntyre¹, C Coleman², L Fox², L Barmat³

¹Department of Obstetrics and Gynecology, Abington Memorial Hospital, 1200 Old York Road, Abington, PA, United States, 19001;

²Department of Scientific and Clinical Affairs, Medifast, Inc., 11445 Cronhill Drive, Owings Mills, MD, United States, 21117 and ; ³Department of Obstetrics and Gynecology, Grand View Hospital, 700 Lawn Avenue, Sellersville, PA, United States, 18960.

PURPOSE/OBJECTIVE:

To evaluate the efficacy of a hypocaloric diet program utilizing a health coach on body weight and changes in biochemical and metabolic profiles in obese PCOS patients.

METHODS/DESIGN:

A prospective study conducted in a teaching community hospital. Subjects were obese (BMI 33.1 ± 3.0), adult, nonpregnant women age 20-39 (27.7 ± 6.1) with PCOS defined by Rotterdam criteria. Subjects were eligible if they were free of hormonal medications for ≥ 3 months, were nonsmokers, and did not have diabetes or hypertension. For 3 months patients followed a 1000 calorie diet plan with the guidance of a health coach consisting of 5 Medifast meals and one self-prepared meal. Meetings with the health coach, weight measurement, and lab draws occurred on a monthly basis. The primary outcome was change in body weight; secondary outcomes were biochemical and metabolic changes. Paired t-tests were used to examine the longitudinal changes from baseline. Significance was defined as $p < 0.05$.

RESULTS:

Eleven subjects completed the study. The hypocaloric diet resulted in significant decline in body weight (-18.2 ± 6.85 lbs; $p < 0.0001$), 2-hour oral glucose (-23.0 ± 22.4 mg/dl; $p = 0.010$), 2-hour insulin (-79.1 ± 76.6 μ U/ml; $p = 0.022$), and calculated free androgen index (-3.7 ± 2.54 ; $p = 0.017$). There was a marginally significant increase in SHGB ($+9.2 \pm 14.1$ nmol/L; $p = 0.069$). For subjects with elevated levels at baseline, significant improvements were found in total cholesterol (-37.0 ± 13.90 mg/dl; $p = 0.013$), LDL cholesterol (-28.0 ± 10.80 mg/dl; $p = 0.014$), and triglycerides (-90.0 ± 1.41 mg/dl; $p = 0.007$). Overall, 1/3 of previously anovulatory women began ovulating and 7 out of 11 began regular menstruation.



CONCLUSIONS:

Significant improvements in body weight and biochemical and metabolic markers were achieved in obese PCOS subjects after 3 months following a hypocaloric portion controlled diet plan under the guidance of a health coach making conditions more favorable for ovulation.

REFERENCE:

This abstract was accepted and presented as a poster at the American Society for Reproductive Medicine's 67th Annual Meeting in 2011. Yuh J, Debrakeleer D, McIntyre W, Coleman C, Fox L, Barmat, L. Efficacy of a Hypocaloric Weight Management Program in Obese Women with Polycystic Ovarian Syndrome (PCOS)[abstract]. 9th Annual Meeting of Androgen Excess & PCOS Society; 2011 Oct 13 – 15; Abstract nr 21.



Seniors

Miller (2021)

Incorporating Nutrition, Vests, Education and Strength Training (INVEST) in Bone Health: Trial Design and Methods

RM Miller¹, DP Beavers², PM Cawthon^{5,6}, C Crotts¹, J Fanning¹, J Gerosa⁷, KA Greene⁴, KL Hsieh¹, J Kiel⁸, E Lawrence¹, L Lenchik³, SD Lynch⁴, BA Nesbit⁷, BJ Nicklas¹, AA Weaver⁴, KM Beavers⁷

¹Department of Internal Medicine-Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America; ²Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, United States of America; ³Department of Diagnostic Radiology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America; ⁴Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, United States of America; ⁵Research Institute, California Pacific Medical Center, San Francisco, CA, United States of America; ⁶Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States of America; ⁷Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States of America; ⁸Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, United States of America.

PURPOSE/OBJECTIVE:

Achievement of 5–10% weight loss (WL) among older adults living with obesity considerably improves prognosis of health-related outcomes; however, concomitant declines in bone mineral density (BMD) limit overall benefit by increasing fracture risk. Declines in mechanical loading contribute to WL-associated BMD loss, with pilot data signaling the addition of external weight replacement (via weighted vest use) during intentional WL mitigates bone loss at weight bearing sites to a similar degree as resistance exercise training (RT). Definitive data in support of weighted vest use as a potential strategy to mitigate WL-associated bone loss in this population are needed.

METHODS/DESIGN:

In the Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health trial (NCT04076618), 192 older adults (60–85 years) who are overweight (BMI ≥ 27 kg/m²) with at least one obesity-related risk factor or obese (BMI=30–40 kg/m²) will be randomly assigned to participate in one of three 12-month intervention groups: WL alone, WL + weighted vest use (WL + VEST), or WL + RT. The primary aim is to determine the effects of WL + VEST compared to WL alone and WL + RT on indicators of bone health and subsequent fracture risk.

DISCUSSION:

Determining effective, translatable strategies that minimize bone loss during intentional WL among older adults holds public health potential. The INVEST in Bone Health trial offers an innovative approach for increasing mechanical stress during intentional WL in the absence of RT. If successful, findings from this study will provide evidence in support of a scalable solution to minimize bone loss during intentional WL among older adults with obesity

REFERENCE:

Miller R. M., Beavers D. P., Cawthon P. M., Crotts C., Fanning J., Gerosa J., Greene K. A., Hsieh K. L., Kiel J., Lawrence E., Lenchik L., Lynch S. D., Nesbit B. A., Nicklas B. J., Weaver A. A., Beavers K. M. (2021). Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health: Trial Design and Methods. *Contemp Clin Trials*. 2021, 104. doi: <https://doi.org/10.1016/j.cct.2021.106326>.

Quillen (2020)

Use of Metabolomic Profiling to Understand Variability in Adiposity Changes Following an Intentional Weight Loss Intervention in Older Adults

EE Quillen¹, DP Beavers², AOB Cox³, CM Furdu^{1,3}, J Lee^{1,3}, RM Miller⁴, H Wu^{1,3}, KM Beavers⁵

¹Internal Medicine, Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; ²Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA; ³Proteomics and Metabolomics Shared Resource, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; ⁴Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; ⁵Health and Exercise Science, Wake Forest University, Winston-Salem, NC 27109, USA.

PURPOSE/OBJECTIVE:

Inter-individual response to dietary interventions remains a major challenge to successful weight loss among older adults. This study applied metabolomics technology to identify small molecule signatures associated with a loss of fat mass and overall weight in a cohort of older adults on a nutritionally complete, high-protein diet.

METHODS/DESIGN:

A total of 102 unique metabolites were measured using liquid chromatography-mass spectrometry (LC-MS) for 38 adults aged 65–80 years randomized to dietary intervention and 36 controls. Metabolite values were analyzed in both baseline plasma samples and samples collected following the six-month dietary intervention to consider both metabolites that could predict the response to diet and those that changed in response to diet or weight loss.

RESULTS:

Eight metabolites changed over the intervention at a nominally significant level: D-pantothenic acid, L-methionine, nicotinate, aniline, melatonin, deoxycarnitine, 6-deoxy-L-galactose, and 10-hydroxydecanoate. Within the intervention group, there was broad variation in the achieved weight-loss and dual-energy x-ray absorptiometry (DXA)-defined changes in total fat and visceral adipose tissue (VAT) mass. Change in the VAT mass was significantly associated with the baseline abundance of α -amino adipate ($p=0.0007$) and an additional mass spectrometry peak that may represent D-fructose, myo-inositol, mannose, α -D-glucose, allose, D-galactose, D-tagatose, or L-sorbose ($p=0.0001$).



CONCLUSIONS:

This hypothesis-generating study reflects the potential of metabolomics biomarkers for the development of personalized dietary interventions.

REFERENCE:

Quillen E.E., Beavers D.P., Cox A.O.B., Furdui C.M., Lee J., Miller R.M., Wu H., Beavers K.M. (2020). Use of Metabolomic Profiling to Understand Variability in Adiposity Changes Following an Intentional Weight Loss Intervention in Older Adults. *Nutrients*, 12(10), 3188. <https://doi.org/10.3390/nu12103188>.

Serra (2019)

Effects of a Hypocaloric, Nutritionally Complete, Higher Protein Meal Plan on Regional Body Fat and Cardiometabolic Biomarkers in Older Adults with Obesity

MC Serra¹, DP Beavers², RM Henderson³, JL Kelleher¹, JR Kiel⁴, KM Beavers⁵

¹Department of Medicine, Atlanta VA Medical Center, Emory University School of Medicine, Atlanta, GA, USA; ²Department of Biostatistical Science, Wake Forest School of Medicine, Winston-Salem, NC, USA; ³Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Winston-Salem, NC, USA; ⁴Medifast, Inc., Baltimore, MD, USA; ⁵Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.

PURPOSE/OBJECTIVE:

Whether improvements in cardiometabolic health following weight loss (WL) are associated with changes in regional body fat distribution (gluteal vs. android) is not well documented.

METHODS/DESIGN:

Older (age: 70 ± 4 years; mean \pm SD) adults with obesity were randomized to a 6-month WL program (WL; $n=47$), accomplished using a hypocaloric, nutritionally complete, higher protein (targeting ≥ 1.0 g/kg/day) meal plan, or a weight stability (WS; $n=49$) program. Android, gynoid, visceral, and subcutaneous abdominal fat masses (via dual energy X-ray absorptiometry) and fasting glucose and lipid profiles were assessed at baseline and 6 months.

RESULTS:

The WL group lost more body weight (WL: -8.6% vs. WS: -1.7% , $p<0.01$), resulting in a reduction in fat mass at each region only following WL (all $p<0.05$). The decline in the ratio of android/gynoid fat mass also was significant only following WL, resulting in greater declines than WS (mean [95% CI]; WL: -0.026 [-0.040 to -0.011] vs. WS: 0.003 [-0.012 to 0.019] g, $p<0.01$). The change in the ratio of visceral/subcutaneous abdominal fat mass was not significant in either group and did not differ between groups (WL: 0.65 [-0.38 to 1.68] vs. WS: 0.05 [-1.00 to 1.10] g, $p=0.42$). In general, the improvements in glucose and lipid profiles were associated with declines in fat mass at the gynoid and android regions (r 's = 0.20 – 0.42 , all $p<0.05$), particularly the visceral depot but not the ratios.



CONCLUSIONS:

WL achieved via a hypocaloric, nutritionally complete, higher protein meal plan is effective in reducing body fat in the android, gynoid, and visceral depots, which relate to cardiometabolic improvements.

REFERENCE:

Serra M.C., Beavers D.P., Henderson R.M., Kelleher J.L., Kiel J.R., Beavers K.M. (2019) Effects of a Hypocaloric, Nutritionally Complete, Higher Protein Meal Plan on Regional Body Fat and Cardiometabolic Biomarkers in Older Adults with Obesity. *Ann Nutr Metab.*, 74(2):149-155. doi: [10.1159/000497066](https://doi.org/10.1159/000497066).

Weaver (2019)

Effect of a Hypocaloric, Nutritionally Complete, Higher Protein Meal Plan on Bone Density and Quality in Older Adults with Obesity: A Randomized Trial

AA Weaver¹, DK Houston², SA Shapses³, MF Lyles², RM Henderson², DP Beavers⁴, AC Baker¹, KM Beavers⁵

¹Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC; ²Department of Internal Medicine, Section on Gerontology and Geriatric Medicine; ³Department of Nutritional Sciences; ⁴Department of Biostatistical Sciences, Rutgers University, New Brunswick, NJ; ⁵Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC.

PURPOSE/OBJECTIVE:

Dietary protein and micronutrients are important to the maintenance of bone health, and may be an effective counter measure to weight-loss-associated bone loss.

We aimed to determine the effect of a 6-mo hypocaloric, nutritionally complete higher-protein meal plan on change in bone density and quality as compared with weight stability in older adults using a randomized post-test design. We hypothesized that participants randomly assigned to this meal plan would maintain similar bone density and quality to weight-stable controls, despite significant reductions in body mass.

METHODS/DESIGN:

Ninety-six older adults (70 ± 3.7 y, 74% women, 27% African American) with obesity [body mass index (kg/m²): 35.4 ± 3.3] were randomly assigned to a 6-mo hypocaloric, nutritionally complete, higher-protein meal plan targeting ≥1.0 g protein · kg body weight¹ · d⁻¹ [weight loss (WL) group; n=47] or to a weight-stability (WS) group targeting 0.8 g protein · kg body weight¹ · d⁻¹, the current Recommended Dietary Allowance (n=49). The primary outcome was total hip bone mineral density (BMD), with femoral neck BMD, lumbar spine BMD, and lumbar spine trabecular bone score (TBS) as secondary outcomes, all assessed at baseline and 3 and 6 mo with dual-energy X-ray absorptiometry.

RESULTS:

Baseline total hip, femoral neck, and lumbar spine BMDs were 1.016 ± 0.160, 0.941 ± 0.142, and 1.287 ± 0.246 g/cm², respectively; lumbar TBS was 1.398 ± 0.109. Despite significant weight loss achieved in the WL group (6.6 ± 0.4 kg; 8.6% ± 0.4% of baseline weight), 6-mo regional BMD estimates were similar to the WS group (all p>0.05). Lumbar spine TBS significantly increased at 6 mo in the WL group (mean: 1.421; 95% CI:1.401, 1.441) compared with the WS group (1.390; 95% CI:1.370, 1.409; p=0.02).



CONCLUSIONS:

Older adults on a hypocaloric, nutritionally complete higher-protein meal plan maintained similar bone density and quality to weight-stable controls. Our data suggest adherence to this diet does not produce loss of hip and spine bone density in older adults, and may improve bone quality. This trial was registered at clinicaltrials.gov as [NCT02730988](https://clinicaltrials.gov/ct2/show/study/NCT02730988).

REFERENCE:

Weaver A.A., Houston D.K., Shapses S.A., Lyles M.F., Henderson R.M., Beavers D.P., Baker A.C., Beavers K.M. (2019) Effect of a Hypocaloric, Nutritionally Complete, Higher Protein Meal Plan on Bone Density and Quality in Older Adults with Obesity: A Randomized Trial. *Am J Clin Nutr.* 109(2):478-486. doi: <https://doi.org/10.1093/ajcn/nqy237>.

Beavers (2018)

Effect of an Energy-Restricted, Nutritionally Complete, Higher Protein Meal Plan on Body Composition and Mobility in Older Adults with Obesity: A Randomized Controlled Trial

KM Beavers¹, BA Nesbit¹, JR Kiel², JL Sheedy¹, LM Arterburn², AE Collins¹, SA Ford¹, RM Henderson³, CD Coleman², DP Beavers⁴

¹Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina; ²Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland; ³Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Winston-Salem, North Carolina; ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.

PURPOSE/OBJECTIVE:

Increasing protein content of the diet might be an effective strategy to preserve muscle mass in older adults undergoing caloric restriction, thereby preserving muscle function.

METHODS/DESIGN:

Ninety-six older adults (70 ± 3.7 years, 74% women, 27% African American) with obesity (35.4 ± 3.3 kg/m²; 47% total body fat) were randomized to a 6-month higher protein (providing 1.2-1.5 g/kg/d) weight loss (WL) program, utilizing the Medifast 4&2&1 Plan, or to weight stability (WS). Dual-energy x-ray absorptiometry-acquired total body mass and composition, and fast gait speed over 400 m was assessed at baseline, 3, and 6 months.

RESULTS:

At baseline, dual-energy x-ray absorptiometry-acquired total body, fat, and lean masses were 95.9 ± 14.6, 44.6 ± 7.6, and 48.7 ± 9.5 kg, respectively, and 400-m gait speed was 1.17 ± 0.20 m/s. Total body mass was significantly reduced in the WL group (-8.17 [-9.56, -6.77] kg) compared to the WS group (-1.16 [-2.59, 0.27] kg), with 87% of total mass lost as fat (WL: -7.1 [-8.1, -6.1] kg; -15.9% change from baseline). A differential treatment effect was not observed for change in lean mass (WL: -0.81 [-1.40, -0.23] kg vs WS: -0.24 [-0.85, 0.36] kg). Four-hundred-meter gait speed was also unchanged from baseline although trends suggest slightly increased gait speed in the WL group [0.01 (-0.02, 0.04) m/s] compared with the WS group [-0.02 (-0.05, 0.01) m/s].



CONCLUSIONS:

Intentional weight loss using a high-protein diet is effective in producing significant total body mass and fat mass loss, while helping preserve lean body mass and mobility, in relatively high-functioning older adults with obesity.

REFERENCE:

Beavers K.M., Nesbit B.A., Kiel J.R., Sheedy J.L., Arterburn L.M., Collins A.E., Ford S.A., Henderson R.M., Coleman C.D., Beavers D.P. (2018) Effect of an Energy Restricted, Nutritionally Complete, Higher Protein Meal Plan on Body Composition and Mobility in Older Adults with Obesity: A Randomized Controlled Trial. *J Gerontol A Bio Sci Med Sci*. doi: [10.1093/gerona/gly146](https://doi.org/10.1093/gerona/gly146).

Shaver (2018)

Effect of Intentional Weight Loss on Mortality Biomarkers in Older Adults With Obesity

LN Shaver¹, DP Beavers², J Kiel³, SB Kritchevsky⁴, KM Beavers¹

¹Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina. ²Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. ³Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, Maryland. ⁴Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.

PURPOSE/OBJECTIVE:

Observational research has identified several mortality biomarkers; however, their responsiveness to change is unknown. We tested whether the Healthy Aging Index (HAI) and other mortality biomarkers were responsive to intentional weight loss (WL), which is associated with lower mortality risk in recent meta-analyses.

METHODS/DESIGN:

Older adults (70.3 ± 3.7 years) with obesity were randomized into a 6-month WL ($n=47$) or weight stability (WS: $\pm 5\%$ baseline weight; $n=48$) program. Baseline and 6-month HAI score (0–10) was calculated from component sum (each 0–2: systolic blood pressure, forced vital capacity [FVC], creatinine, fasting blood glucose [FBG], Montreal Cognitive Assessment), and gait speed, grip strength, Digit Symbol Substitution Test, FEV1, Interleukin-6, C-Reactive Protein, and Cystatin-C were assessed at baseline and 6 months.

RESULTS:

Mean baseline HAI was 3.2 ± 1.6 . By 6 months, WL participants lost 8.87 (95% CI: $-10.40, -7.34$) kg, whereas WS participants remained weight stable. WL group reduced HAI score (WL: -0.75 [95% CI: $-1.11, -0.39$] vs WS: -0.22 [95% CI: $-0.60, 0.15$]; $p=0.04$), and components changing the most were FBG (WL: -3.89 [95% CI: $-7.78, 0.00$] mg/dL vs WS: 1.45 [95% CI: $-2.61, 5.50$] mg/dL; $p=0.047$) and FVC (WL: 0.11 [95% CI: $-0.01, 0.23$] L vs WS: -0.05 [95% CI: $-0.17, 0.08$] L; $p=0.06$). Among other biomarkers, only Cystatin-C significantly changed (WL: -2.53 [95% CI: $-4.38, -0.68$] ng/mL vs WS: 0.07 [95% CI: $-1.85, 1.98$] ng/mL; $p=0.04$). Combining treatment groups, 1 kg WL was associated with a 0.07 (95% CI: $0.03, 0.12$) HAI reduction ($p<0.01$).



CONCLUSIONS:

Intentional WL via caloric restriction reduced HAI score by 0.53 points, largely attributable to metabolic and pulmonary improvements.

REFERENCE:

Shaver L.N., Beavers D.P., Kiel J., Kritchevsky S.B., Beavers K.M. (2018). Effect of Intentional Weight Loss on Mortality Biomarkers in Older Adults with Obesity. *Gerontol A Biol Sci Med Sci.*, 2018; 74(8):1303-1309. doi: [10.1093/gerona/gly192](https://doi.org/10.1093/gerona/gly192).

Normandin (2018)

Feasibility of Weighted Vest use During a Dietary Weight Loss Intervention and Effects on Body Composition and Physical Function in Older Adults

E Normandin¹, D Yow¹, C Crotts¹, J Kiel², KM Beavers³, BJ Nicklas^{1,3}

¹Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; ²Department of Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD 21202, USA; ³Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC 27109, USA.

PURPOSE/OBJECTIVE:

While intentional weight loss in older adults with obesity yields clinically important health benefits there is a need to minimize the negative effects of weight loss on concomitant loss of muscle mass and strength. Data show wearing weighted vests during exercise improves lean mass and lower extremity strength, however the efficacy of wearing a weighted vest during a period of weight loss to mitigate muscle and strength loss is not known.

This study examined the feasibility of daily weighted vest use during a dietary weight loss intervention, and examined effects of vest use on body composition and physical function in well-functioning older adults with obesity.

METHODS/DESIGN:

Design: Randomized, controlled pilot study.

Setting: Wake Forest Baptist Medical Center in Winston-Salem, NC.

Participants: 37 older (age=65-79 years), obese (BMI=30-40 kg/m²) sedentary men and women.

Interventions: 22-week behavioral diet intervention (targeting 10% weight loss, 1100-1300 kcals/day) with (Diet+Vest; n=20) or without (Diet; n=17) weighted vest use (goal of 10 hours/day with weight added weekly according to individual loss of body mass).

Measurements: Body composition by dual-energy x-ray absorptiometry and measures of physical function, mobility, and muscle strength/power.

RESULTS:

Average weighted vest use was 6.7 ± 2.2 hours/day and the vest-wear goal of 10 hrs/day was achieved for 67 ± 22% of total intervention days. Five participants reported adverse events from wearing the vest (all back pain or soreness). Both groups lost a similar amount of weight (Diet= -11.2 ± 4.4 kg; Diet+Vest= -11.0 ± 6.3 kg; p<0.001), with no differences between groups (p=0.25). Fat mass, lean mass, and % body fat decreased significantly (p<0.0001), with no differences between groups. Compared to Diet+Vest, the Diet intervention resulted in greater decreases in leg power (p<0.02), with no other between group differences in physical function.



CONCLUSIONS:

This pilot study showed that vest use during dietary weight loss is feasible and safe in well-functioning older adults with obesity. Larger studies are needed to definitively determine whether external replacement of lost weight during caloric restriction may preserve lower extremity muscle strength and power.

REFERENCE:

Normandin E., Yow D., Crotts C., Kiel J., Beavers K.M., Nicklas B.J. (2018). Feasibility of Weighted Vest Use During A Dietary Weight Loss Intervention and Effects on Body Composition and Physical Function in Older Adults. *J of Frailty & Aging*; 7(3):198-203. doi: [10.14283/jfa.2018.17](https://doi.org/10.14283/jfa.2018.17).

Kelleher (2017)

Weighted Vest Use During Dietary Weight Loss on Bone Health in Older Adults with Obesity

JL Kelleher¹, DP Beavers², RM Henderson³, D Yow³, C Crotts³, J Kiel⁴, BJ Nicklas^{1,3}, KM Beavers¹

¹Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC 27109, USA; ²Department of Biostatistics, Wake Forest University, Winston-Salem, NC 27157, USA; ³Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; ⁴Department of Scientific and Clinical Affairs, Medifast, Inc., Owings Mills, MD 21117, USA.

PURPOSE/OBJECTIVE:

To examine the effects of daily weighted vest use during a dietary weight loss intervention, on (a) hip and spine bone mineral density (aBMD), and (b) biomarkers of bone turnover, in older adults with obesity.

METHODS/DESIGN:

37 older (70.1 ± 3.0 years) adults with obesity ($BMI=35.3 \pm 2.9$) underwent a 22 week dietary weight loss intervention (1100-1300 kcal/day) with (Diet+Vest; $n=20$) or without (Diet; $n=17$) weighted vest use (goal: 10+ h/day; weight added incrementally based on amount of weight lost). Total body weight; DXA-acquired aBMD of the total hip, femoral neck and lumbar spine; and biomarkers of bone turnover (OC, BALP, P1NP, CTX) were measured at baseline and follow up. General linear models, adjusted for baseline values of the outcome and gender, were used to examine intervention effects.

RESULTS:

Average weight loss was significant in both groups (-11.2 ± 4.4 kg and -11.0 ± 6.3 kg, Diet+Vest and Diet groups, respectively), with no difference between groups ($p=0.91$). Average weighted vest use was 6.7 ± 2.2 h/day. No significant changes in aBMD or biomarkers were observed, although trends were noted for total hip aBMD and BALP. Loss in total hip aBMD was greater in the Diet group compared with Diet+Vest ($\Delta: -18.7 [29.3, -8.1]$ mg/cm² versus $-6.1 [-15.7, 3.5]$ mg/cm²; $p=0.08$). BALP increased in the Diet+Vest group by 3.8% ($\Delta: 0.59 [-0.33, 1.50]$ µg/L) and decreased by -4.6% in the Diet group ($\Delta: -0.70 [-1.70, 0.31]$ µg/L, $p=0.07$).



CONCLUSIONS:

Weighted vest use during weight loss may attenuate loss of hip aBMD and increase bone formation in older adults with obesity. Further study is warranted.

REFERENCE:

Kelleher J.L., Beavers D.P., Henderson R.M., Yow D., Crotts C., Kiel J., Nicklas B.J., Beavers K.M. (2017). Weighted Vest Use During Dietary Weight Loss on Bone Health in Older Adults with Obesity. *J Osteopor Phys Act*, 5(4); doi: [10.4172/2329-9509.1000210](https://doi.org/10.4172/2329-9509.1000210).

Beavers (2015)

Effect of Protein Source During Weight Loss on Body Composition, Cardiometabolic Risk and Physical Performance in Abdominally Obese, Older Adults: A Pilot Feeding Study

KM Beavers¹, MM Gordon¹, L Easter², DP Beavers³, KG Hairston⁴, BJ Nicklas¹, MZ Vitolins⁵

¹Department of Internal Medicine, Section on Gerontology and Geriatric Medicine; ²Translational Science Institute; ³Department of Biostatistical Sciences; ⁴Department of Endocrinology and Metabolism; ⁵Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC 27157 USA.

PURPOSE/OBJECTIVE:

The purpose of this pilot study was to begin to examine the effect of dietary protein source (soy protein versus non-soy protein) during weight loss on body composition, and cardiometabolic and functional decline risk factors in older, abdominally obese adults.

METHODS/DESIGN:

Design: Two-arm, single-blind, randomized, controlled trial. Setting: Wake Forest School of Medicine, Winston-Salem NC 27157, USA.

Participants: 25 older (68.4 ± 5.5 years, 88% female), abdominally obese (BMI: 35.1 ± 4.3 kg/m²; WC: 101.4 ± 13.1 cm) men and women were randomized to participate in the study.

Intervention: A 12-week weight loss intervention, with participants randomized to consume soy protein-based meal replacements (S; n=12) or non-soy protein-based meal replacements (NS; n=12), in addition to prepared meals, and all participants targeted to receive an individualized calorie deficit of 500 kcal/day.

Measurements: Body weight and composition (assessed via DXA and CT), conventional biomarkers of cardiometabolic risk, and physical performance measures were assessed pre- and post-intervention. Additional endpoints of feasibility (accrual, participation, retention, compliance, and safety) are reported.

RESULTS:

A total of 24 participants (87% female) completed the study (96% retention) and lost an average of 7.8 ± 3.0 kg over the 12-week period, with no difference seen between groups (p=0.83). Although nearly all measures of global and regional body composition were significantly reduced following the 12-week intervention, differences were not observed between groups. Among cardiometabolic risk factors and physical performance measures, only diastolic blood pressure was significantly lower in the NS group compared to the S group (66.7 ± 2.7 mmHg vs 73.5 ± 2.7 mmHg, respectively; p=0.04). Interestingly, in groups combined, despite significant reductions in body weight and lean mass, no significant changes in the 400-meter walk time (+5.3 ± 43.4 s), short physical performance battery score (+0.1 ± 1.0), grip strength (-0.3 ± 3.2 kg), or relative knee extensor strength (-0.0 ± 0.0 N/m/cm³ thigh muscle volume) were observed.



CONCLUSIONS:

Data presented here suggest that a 12-week weight loss intervention, which incorporates S and NS meal replacement products, is associated with clinically significant weight loss and improvements in several parameters of cardiometabolic risk and unchanged physical function and strength. Results do not differ by protein source and suggest that soy protein is at least as good as other protein sources for weight loss during low-calorie dietary interventions in older adults.

REFERENCE:

Beavers K.M., Gordon M.M., Easter L., Beavers D.P., Hairston K.G., Nicklas B.J., Vitolins M.Z. (2015). Effect of Protein Source during Weight Loss on Body Composition, Cardiometabolic Risk and Physical Performance in Abdominally Obese, Older Adults: A Pilot Feeding Study. *J Nutr Health Aging*, 19(1), 87-95. doi: [10.1007/s12603-015-0438-7](https://doi.org/10.1007/s12603-015-0438-7); [PMC4818969](https://pubmed.ncbi.nlm.nih.gov/2618969/).



Soy

Messina (2022)

The Health Effects of Soy: A Reference Guide for Health Professionals

M Messina¹, A Duncan², V Messina³, H Lynch⁴, J Kiel⁵, JW Erdman Jr.⁶

¹Soy Nutrition Institute Global, Washington, DC, United States; ²Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada; ³Nutrition Matters, Inc, Pittsfield, MA, United States; ⁴Kinesiology Department, Point Loma Nazarene University, San Diego, CA, United States; ⁵Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, United States; ⁶Division of Nutritional Sciences and Beckman Institute, Department of Food Science and Human Nutrition, University of Illinois at Urbana/Champaign, Urbana, IL, United States.

ABSTRACT:

Soy is a hotly debated and widely discussed topic in the field of nutrition. However, health practitioners may be ill-equipped to counsel clients and patients about the use of soyfoods because of the enormous, and often contradictory, amount of research that has been published over the past 30 years. As interest in plant-based diets increases, there will be increased pressure for practitioners to gain a working knowledge of this area. The purpose of this review is to provide concise literature summaries (400–500 words) along with a short perspective on the current state of knowledge of a wide range of topics related to soy, from the cholesterol-lowering effects of soy protein to the impact of isoflavones on breast cancer risk. In addition to the literature summaries, general background information on soyfoods, soy protein, and isoflavones is provided. This analysis can serve as a tool for health professionals to be used when discussing soyfoods with their clients and patients.

REFERENCE:

Messina M., Duncan A., Messina V., Lynch H., Kiel J., Erdman JW Jr. (2022). The Health Effects of Soy: A Reference Guide for Health Professionals. *Front Nutr.* 2022 Aug 11;9:970364. doi: [10.3389/fnut.2022.970364](https://doi.org/10.3389/fnut.2022.970364).

Messina (2022)

Perspective: Soy-based Meat and Dairy Alternatives, Despite Classification as Ultra-processed Foods, Deliver High-quality Nutrition on Par with Unprocessed or Minimally Processed Animal-based Counterparts

MJ Messina¹, JL Sievenpiper^{2,3,4}, P Williamson⁵, J Kiel⁶, JW Erdman Jr.⁷

¹Soy Nutrition Institute Global, Washington, DC, USA; ²Departments of Nutritional Sciences and Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; ³Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; ⁴Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; ⁵Scientific and Regulatory Affairs, Research and Development, Cargill, Wayzata, MN, USA; ⁶Scientific and Clinical Affairs, Medifast, Inc., Baltimore, MD, USA; and ⁷Department of Food Science and Human Nutrition, Division of Nutritional Sciences and Beckman Institute, University of Illinois at Urbana/Champaign, Urbana, IL, USA.

ABSTRACT:

In many non-Asian countries, soy is consumed via soy-based meat and dairy alternatives, in addition to the traditional Asian soyfoods, such as tofu and miso. Meat alternatives are typically made using concentrated sources of soy protein, such as soy protein isolate (SPI) and soy protein concentrate (SPC). Therefore, these products are classified as ultra-processed foods (UPFs; group 4) according to NOVA, an increasingly widely used food-classification system that classifies all foods into 1 of 4 groups according to the processing they undergo. Furthermore, most soymilks, even those made from whole soybeans, are also classified as UPFs because of the addition of sugars and emulsifiers. Increasingly, recommendations are being made to restrict the consumption of UPFs because their intake is associated with a variety of adverse health outcomes. Critics of UPFs argue these foods are unhealthful for a wide assortment of reasons. Explanations for the proposed adverse effects of UPFs include their high energy density, high glycemic index (GI), hyper-palatability, and low satiety potential. Claims have also been made that UPFs are not sustainably produced. However, this perspective argues that none of the criticisms of UPFs apply to soy-based meat and dairy alternatives when compared with their animal-based counterparts, beef and cow milk, which are classified as unprocessed or minimally processed foods (group 1). Classifying soy-based meat and dairy alternatives as UPFs may hinder their public acceptance, which could detrimentally affect personal and planetary health. In conclusion, the NOVA classification system is simplistic and does not adequately evaluate the nutritional attributes of meat and dairy alternatives based on soy.

STATEMENT OF SIGNIFICANCE:

NOVA classifies soymilk and soy-based meat alternatives as ultra-processed foods (UPFs). However, criticisms of UPFs are not applicable to these foods when they are compared with their animal-based counterparts, which are classified as unprocessed or minimally processed foods. Admonitions against soymilk and soy-based meat alternatives based on their NOVA classification may dissuade consumers from consuming foods that offer health and environmental benefits

REFERENCE:

Messina M.J., Sievenpiper J.L., Williamson P., Kiel J., Erdman J.W. Jr. (2022). Perspective: Soy-based Meat and Dairy Alternatives, Despite Classification as Ultra-processed Foods, Deliver High-quality Nutrition on Par with Unprocessed or Minimally Processed Animal-based Counterparts. *Adv Nutr.*, 2021(13)2:726-738. <https://doi.org/10.1093/advances/nmac026>.



Teenagers

Cheskin (2007)

A RCT Comparing Balanced Energy Deficit Diets With or Without Meal Replacements for Weight Loss and Maintenance Among Children Dieting Alone or With a Parent

LJ Cheskin, AH Mitola, A Mitchell, A Jhaveri, V Mitchell

International Health/Nutrition. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PURPOSE/OBJECTIVE:

We compared the safety and efficacy of supplemental Medifast portion-controlled meal replacements (MRs) with a USDA Food Guide Pyramid-based diet.

METHODS/DESIGN:

Both weight loss diets were 20% energy restricted (~500 kcal deficit). Eighty 8-15 year old children, BMI >95th%ile, were screened and 40 randomized to either a MR diet (3 MRs/day during active weight loss and 2 MRs/day during maintenance) or to the food-based diet. Subjects were further randomized to dieting alone or with a parent.

RESULTS:

By ITT analysis, dieting with a parent, or food vs MR, made no difference in weight outcome. However, following initial weight loss (6 months) and 1 year maintenance (18 months), significant ($p < 0.05$) decreases were seen in the MR group in BMI%ile (0 months = 98.8 ± 1.0 , 6 months = 96.6 ± 3.2 , 18 months = 96.4 ± 3.4); body fat (5.9% at 6 months, 5.3% at 18 months); total cholesterol (6.7% [at 6 months], 5.6% [at 18 months]); LDL (19.8% [at 6 months], 7.9% [at 18 months]); and triglycerides (23.6% [at 6 months], 22.3% [at 18 months]). No significant between-group differences, differences in growth rates, or adverse events were observed.



CONCLUSIONS:

Among overweight 8-15 year old children, dieting with or without a parent, meal replacements were as safe and effective as a food-based diet for weight loss and maintenance.

REFERENCE:

This abstract was accepted and presented as a poster at the Experimental Biology Conference in 2007.

Cheskin L.J., Hanlon-Mitola A., Mitchell A., Jhaveri A., Yep M., Mitchell, V. (2007). A RCT Comparing Balanced Energy Deficit Diets with or Without Meal Replacements for Weight Loss and Maintenance Among Children Dieting Alone or with a Parent. *FASEB J*, 21, 1b214



Trp64Arg Gene Variant

Tchernof (2000)

Impaired Capacity to Lose Visceral Adipose Tissue During Weight Reduction in Obese Postmenopausal Women with the Trp64Arg β_3 -Adrenoceptor Gene Variant

A Tchernof¹, RD Starling¹, A Turner¹, AR Shuldiner^{2,3}, JD Walston⁴, K Silver^{2,3}, ET Poehlman¹

¹Department of Medicine, College of Medicine, University of Vermont, Burlington, Vermont; ²Department of Medicine, the Division of Endocrinology, Diabetes and Nutrition, University of Maryland; ³Geriatric Research Education and Clinical Center, Baltimore Veterans Administration Medical Center; ⁴Division of Geriatric Medicine and Gerontology, Johns Hopkins University, Baltimore, Maryland.

PURPOSE/OBJECTIVE:

Controversy exists regarding the association between the Trp64Arg variant of the β_3 -adrenoceptor gene and visceral obesity. The cross-sectional nature of most studies, the modest effect of the variant, and the sex or ethnic differences between groups have contributed to discrepancies among investigations. To overcome these confounding factors, we examined the effect of the Trp64Arg variant on total and visceral adipose tissue loss, insulin sensitivity, and cardiovascular disease risk factors in response to weight reduction in obese older women.

METHODS/DESIGN:

A total of 24 women (age 57 ± 4 years), including 1 Trp64Arg homozygote, 10 Trp64Arg heterozygotes, and 13 normal homozygotes, were admitted to a weight reduction program of 13 ± 3 months, with weight and nutritional intake stabilization established before testing. Total and regional adiposity were measured with dual-energy X-ray absorptiometry and computed tomography, insulin sensitivity was measured by the hyperinsulinemic-euglycemic clamp technique, and a blood lipid profile was obtained.

RESULTS:

No baseline differences were noted in adiposity measurements, glucose disposal, and lipid profiles among carriers and noncarriers of the variant allele. In response to weight loss, carriers and noncarriers of the Trp64Arg allele had similar reductions in body weight (-16.4 ± 5.0 vs. -14.1 ± 6.2 kg, NS) and body fat (-10.0 ± 5.2 vs. -11.5 ± 3.9 kg, NS). However, loss of visceral adipose tissue was 43% lower in carriers of the Trp64Arg allele compared with noncarriers (-46 ± 27 vs. -81 ± 51 cm², $p=0.05$). Furthermore, there was less improvement in the total cholesterol-to-HDL cholesterol ratio (-0.18 ± 0.54 vs. -0.72 ± 0.56 , $p=0.04$) in carriers compared with noncarriers of the allele. Although glucose disposal improved in both groups, there was no difference in the magnitude of improvement between carriers and noncarriers of the variant allele.



CONCLUSIONS:

In conclusion, older obese women carrying the Trp64Arg β_3 -adrenoceptor gene variant have an impaired capacity to lose visceral adipose tissue in response to prolonged caloric restriction. Despite these genetic differences in loss of intra-abdominal adipose tissue, improvement in glucose disposal was similar between groups.

REFERENCE:

Tchernof A., Starling R.D., Turner A., Shuldiner A.R., Walston J.D., Silver K., Poehlman E.T. (2000). Impaired Capacity to Lose Visceral Adipose Tissue During Weight Reduction in Obese Postmenopausal Women with the Trp64Arg β_3 -Adrenoceptor Gene Variant. *Diabetes*, 49(10), 1709-1713.



Other

Lynch (2025)

Musculoskeletal Characteristics in Older Adults with Overweight or Obesity: INVEST in Bone Health Trial Baseline Analysis

SD Lynch¹, M Howard², DP Beavers³, L Lenchik⁴, R Barnard², JR Stapleton¹, E Lawrence⁵, PW Cathon⁶, FC Hsu², KM Beavers⁷, AA Weaver¹

¹Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ²Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ³Department of Statistical Sciences, Wake Forest University, Winston-Salem, North Carolina, USA; ⁴Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁵Department of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁶California Pacific Medical Center Research Institute, San Francisco, California, USA; ⁷Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina, USA.

PURPOSE/OBJECTIVE:

The objective of this study was to examine associations of computed tomography (CT)-derived musculoskeletal measures with demographics and traditional musculoskeletal characteristics.

METHODS/DESIGN:

The Incorporating Nutrition, Vests, Education, and Strength Training ([INVEST](#)) in Bone Health trial ([NCT04076618](#)) acquired a battery of musculoskeletal measures in 150 older-aged adults living with overweight or obesity. At baseline, CT (i.e., volumetric bone mineral density, cortical thickness, muscle radiomics, and muscle/intermuscular adipose tissue [IMAT] area and density), dual-energy x-ray absorptiometry (DXA; i.e., areal bone mineral density, total body fat mass, appendicular lean mass, and lean body mass), and strength assessments (i.e., grip and knee extensor strength) were collected, along with demographic and clinical characteristics. Analyses employed linear regression and mixed effects models along with factor analysis for dimensionality reduction of the radiomics data.

RESULTS:

Participants were older-aged (mean [SD] age: 66 [5] years), mostly female (75%), and were living with overweight or obesity (mean [SD] BMI: 33.6 [3.3] kg/m²). Age was not significantly associated with most CT-derived bone, IMAT, or muscle measures. BMI was significantly associated with DXA and CT-derived muscle and IMAT measures, which were higher in male than female individuals (all $p < 0.01$). For the mid thigh, muscle size was significantly related to grip and knee extensor strength (both $p < 0.01$).



CONCLUSIONS:

Machine learning-derived CT metrics correlated strongly with DXA and muscle strength, with higher BMI linked to greater IMAT and poorer muscle quality.

REFERENCE:

Lynch S.D., Howard M., Beavers D.P., Lenchik L., Barnard R., Stapleton J.R., Lawrence E., Cawthon P.M., Hsu F.C., Beavers K.M., Weaver A.A. (2025). Musculoskeletal Characteristics in Older Adults with Overweight or Obesity: INVEST in Bone Health Trial Baseline Analysis. *Obesity*. 2025; 1-14. doi: [10.1002/oby.24243](#).

Beavers (2023)

Application of the D₃-creatine Muscle Mass Assessment Tool to a Geriatric Weight Loss Trial: A Pilot

KM Beavers¹, AE Avery¹, M Shankaran², WJ Evans², SD Lynch³, C Dwyer¹, M Howard⁴, DP Beavers⁵, AA Weaver³, L Lenchik⁶, PM Cawthon⁷

¹Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina, USA; ²University of California, Berkeley, California, USA; ³Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁴Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁵Department of Statistical Sciences, Wake Forest University, Winston-Salem, North Carolina, USA; ⁶Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁷Research Institute, California Pacific Medical Center, San Francisco, California, USA.

PURPOSE/OBJECTIVE:

Traditionally, weight loss (WL) trials utilize dual energy X-ray absorptiometry (DXA) to measure lean mass. This method assumes lean mass, as the sum of all non-bone and non-fat tissue, is a reasonable proxy for muscle mass. In contrast, the D₃-creatine (D₃Cr) dilution method directly measures whole body skeletal muscle mass, although this method has yet to be applied in the context of a geriatric WL trial. The purpose of this project was to (1) describe estimates of change and variability in D₃Cr muscle mass in older adults participating in an intentional WL intervention and (2) relate its change to other measures of body composition as well as muscle function and strength.

METHODS/DESIGN:

The [INVEST](#) in Bone Health trial ([NCT04076618](#)), used as a scaffold for this ancillary pilot project, is a three-armed, 12-month randomized, controlled trial designed to determine the effects of resistance training or weighted vest use during intentional WL on a battery of musculoskeletal health outcomes among 150 older adults living with obesity. A convenience sample of 24 participants (n=8/arm) are included in this analysis. At baseline and 6 months, participants were weighed, ingested a 30 mg D₃Cr tracer dose, provided a fasted urine sample 3–6 days post-dosage, underwent DXA (total body fat and lean masses, appendicular lean mass) and computed tomography (mid-thigh and trunk muscle/intermuscular fat areas) scans, and performed 400-m walk, stair climb, knee extensor strength, and grip strength tests.

RESULTS:

Participants were older (68.0 ± 4.4 years), mostly White (75.0%), predominantly female (66.7%), and living with obesity (body mass index: 33.8 ± 2.7 kg/m²). Six month total body WL was -10.3 (95% confidence interval, CI: -12.7, -7.9) kg. All DXA and computed tomography-derived body composition measures were significantly decreased from baseline, yet D₃Cr muscle mass did not change [+0.5 (95% CI: -2.0, 3.0) kg]. Of muscle function and strength measures, only grip strength significantly changed [+2.5 (95% CI: 1.0, 4.0) kg] from baseline.



CONCLUSIONS:

Among 24 older adults, significant WL with or without weighted vest use or resistance training over a 6-month period was associated with significant declines in all bioimaging metrics, while D₃Cr muscle mass and muscle function and strength were preserved. Treatment assignment for the trial remains blinded; therefore, full interpretation of these findings is limited. Future work in this area will assess change in D₃Cr muscle mass by parent trial treatment group assignment in all study participants.

REFERENCE:

Beavers K.M., Avery A.E., Shankaran M., Evans W.J., Lynch S.D., Dwyer C., Howard M., Beavers D.P., Weaver A.A., Lenchik L., Cawthon P.M. (2023). Application of the D₃Cr Muscle Mass Assessment Tool to a Geriatric Weight Loss Trial: A Pilot Study. *J Cachexia Sarcopenia Muscle*. 2023;14: 2350-2358. <https://doi.org/10.1002/jcsm.13322>

Mishra (2023)

A Mechanism by Which Gut Microbiota Elevates Permeability and Inflammation in Obese/Diabetic Mice and Human Gut

SP Mishra^{1,2}, B Wang³, S Jain^{1,2}, J Ding⁴, J Rejeski⁴, CM Furdui⁴, DW Kitzman^{4,5}, S Taraphder⁶, C Brechot⁷, A Kumar⁷, H Yadav^{1,2}

¹Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa, Florida, USA; ²USF Center for Microbiome Research, Microbiomes Institutes, University of South Florida Morsani College of Medicine, Tampa, Florida, USA; ³Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology, Melbourne, Florida, USA; ⁴Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; ⁵Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; ⁶Department of Animal Genetics and Breeding, West Bengal University of Animal & Fishery Sciences, Kolkata, West Bengal, India; ⁷Department of Internal Medicine, University of South Florida College of Medicine, Tampa, Florida, USA.

PURPOSE/OBJECTIVE:

Ample evidence exists for the role of abnormal gut microbiota composition and increased gut permeability ('leaky gut') in chronic inflammation that commonly co-occurs in the gut in both obesity and diabetes, yet the detailed mechanisms involved in this process have remained elusive.

METHODS/DESIGN:

In this study, we substantiate the causal role of the gut microbiota by use of faecal conditioned media along with faecal microbiota transplantation. Using untargeted and comprehensive approaches, we discovered the mechanism by which the obese microbiota instigates gut permeability, inflammation and abnormalities in glucose metabolism

RESULTS:

We demonstrated that the reduced capacity of the microbiota from both obese mice and humans to metabolise ethanolamine results in ethanolamine accumulation in the gut, accounting for induction of intestinal permeability. Elevated ethanolamine increased the expression of microRNA-miR-101a-3p by enhancing ARID3a binding on the miR promoter. Increased miR-101a-3p decreased the stability of zona occludens-1 (Zo1) mRNA, which in turn, weakened intestinal barriers and induced gut permeability, inflammation and abnormalities in glucose metabolism. Importantly, restoring ethanolamine-metabolising activity in gut microbiota using a novel probiotic therapy reduced elevated gut permeability, inflammation and abnormalities in glucose metabolism by correcting the ARID3a/miR-101a/Zo1 axis.



CONCLUSIONS:

Overall, we discovered that the reduced capacity of obese microbiota to metabolise ethanolamine instigates gut permeability, inflammation and glucose metabolic dysfunctions, and restoring ethanolamine-metabolising capacity by a novel probiotic therapy reverses these abnormalities.

REFERENCE:

Mishra S.P., Wang B., Jain S., Ding J., Rejeski J., Furdui C.M., Kitzman D.W., Taraphder S., Brechot C., Kumar A., Yadav H. (2023). A Mechanism by Which Gut Microbiota Elevates Permeability and Inflammation in Obese/Diabetic Mice and Human Gut. *Gut*. 2023 Oct;72(10):1848-1865. doi: [10.1136/gutjnl-2022-327365](https://doi.org/10.1136/gutjnl-2022-327365).





©2026 Trilivys, Inc. All Rights Reserved.

Medifast_Clinical-Studies-Overview_071626